UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 10-Q
(Mark One)
   
þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.
For the quarterly period ended June 30,December 31, 2010
Or
   
o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 000-33009
MEDCATH CORPORATION
(Exact name of registrant as specified in its charter)
   
Delaware
56-2248952
(State or other jurisdiction of
(IRS Employer Identification No.)
incorporation or organization) 56-2248952
(IRS Employer Identification No.)
10720 Sikes Place, Suite 300
Charlotte, North Carolina 28277

(Address of principal executive offices, including zip code)
(704) 815-7700
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yesþ Noo
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yeso Nooþ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated fileroAccelerated filerþ Non-accelerated filero
Smaller reporting companyo
(Do not check if a smaller reporting company)Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yeso Noþ
As of August 5, 2010,February 4, 2011, there were 20,492,36620,308,070 shares of $0.01 par value common stock outstanding.
 
 

 


 

MEDCATH CORPORATION
FORM 10-Q
TABLE OF CONTENTS
     
  Page 
  13 
  13 
1
2
  3 
  4
5
6 
  57 
  2018 
  3326 
  3326 
  3426 
  3426 
  34
3526 
  3626 
  3628 
EX-10.1
EX-10.2
EX-10.3
EX-10.4
 EX-31.1
 EX-31.2
 EX-32.1
 EX-32.2

2


PART I. FINANCIAL INFORMATION
Item 1. Unaudited Consolidated Financial Statements
MEDCATH CORPORATION
MEDCATH CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands, except per share data)
(Unaudited)
                
 June 30, September 30,  December 31, September 30, 
 2010 2009  2010 2010 
  
Current assets:  
Cash and cash equivalents $27,396 $31,883  $158,475 $33,141 
Accounts receivable, net (See Note 4) 61,230 58,913 
Accounts receivable, net 44,795 43,811 
Income tax receivable 1,192    6,188 
Medical supplies 15,888 15,459  10,644 10,550 
Deferred income tax assets 12,272 12,161  7,815 13,247 
Prepaid expenses and other current assets 13,711 13,471  12,902 13,453 
Current assets of discontinued operations 26,172 44,978  57,345 47,920 
          
Total current assets 157,861 176,865  291,976 168,310 
Property and equipment, net (See Note 13) 289,861 341,394 
Investments in affiliates 10,301 14,055 
Property and equipment, net 176,885 182,222 
Other assets 7,460 10,785  11,652 24,716 
Deferred income tax assets 603  
Non-current assets of discontinued operations 46,741 47,349  1,232 119,290 
          
Total assets $512,827 $590,448  $481,745 $494,538 
          
  
Current liabilities:  
Accounts payable $27,559 $35,920  $19,957 $15,716 
Income tax payable  297  14,316  
Accrued compensation and benefits 17,148 16,118  11,705 16,418 
Other accrued liabilities 20,647 23,277  21,073 16,663 
Current portion of long-term debt and obligations under capital leases 15,808 21,187  61,573 16,672 
Current liabilities of discontinued operations 19,062 19,832  17,014 35,044 
          
Total current liabilities 100,224 116,631  145,638 100,513 
Long-term debt 56,250 66,563   52,500 
Obligations under capital leases 7,459 4,596  5,822 6,500 
Deferred income tax liabilities  13,874 
Other long-term obligations 5,262 8,533  3,883 5,053 
Long-term liabilities of discontinued operations 35,872 35,721   35,968 
          
Total liabilities 205,067 245,918  155,343 200,534 
  
Commitments and contingencies (See Note 7)  
  
Redeemable noncontrolling interest (See Note 1) 6,095 7,448 
Redeemable noncontrolling interest in equity of consolidated subsidiaries 5,812 11,534 
  
Stockholders’ equity:  
Preferred stock, $0.01 par value, 10,000,000 shares authorized; none issued      
Common stock, $0.01 par value, 50,000,000 shares authorized; 22,446,727 issued and 20,492,366 outstanding at June 30, 2010 22,104,917 issued and 20,150,556 outstanding at September 30, 2009 216 216 
Common stock, $0.01 par value, 50,000,000 shares authorized; 22,262,431 issued and 20,308,070 outstanding at December 31, 2010 22,423,666 issued and 20,469,305 outstanding at September 30, 2010 216 216 
Paid-in capital 457,058 455,259  457,952 457,725 
Accumulated deficit  (118,102)  (91,420)  (102,752)  (139,791)
Accumulated other comprehensive loss  (395)  (360)   (444)
Treasury stock, at cost; 1,954,361 shares at June 30, 2010 1,954,361 shares at September 30, 2009  (44,797)  (44,797)
Treasury stock, at cost; 1,945,361 shares at December 31, 2010 and September 30, 2010  (44,797)  (44,797)
          
Total MedCath Corporation stockholders’ equity 293,980 318,898  310,619 272,909 
Noncontrolling interest 7,685 18,184  9,971 9,561 
          
Total equity 301,665 337,082  320,590 282,470 
          
Total liabilities and equity $512,827 $590,448  $481,745 $494,538 
          
See notes to unaudited consolidated financial statements.

1


MEDCATH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)

(Unaudited)
                 
  Three Months Ended June 30,  Nine Months Ended June 30, 
  2010  2009  2010  2009 
                 
Net revenue $131,847  $124,588  $390,815  $381,410 
Operating expenses:                
Personnel expense  44,546   43,854   136,055   131,884 
Medical supplies expense  35,706   36,472   107,453   105,829 
Bad debt expense  13,642   10,406   36,241   28,798 
Other operating expenses  29,935   26,537   89,292   81,039 
Pre-opening expenses     754   866   1,340 
Depreciation  7,636   6,466   23,054   19,179 
Amortization  8   8   24   24 
Impairment of property and equipment  22,813      42,761    
Loss (gain) on disposal of property, equipment and other assets  20   (54)  39   127 
             
Total operating expenses  154,306   124,443   435,785   368,220 
             
(Loss) income from operations  (22,459)  145   (44,970)  13,190 
Other income (expenses):                
Interest expense  (1,131)  (396)  (3,337)  (3,074)
Loss on early extinguishment of debt           (6,702)
Interest and other income  62   48   156   220 
Loss on note receiveable        (1,507)   
Equity in net earnings of unconsolidated affiliates  2,262   2,265   6,870   7,044 
             
Total other income (expense), net  1,193   1,917   2,182   (2,512)
             
(Loss) income from continuing operations before income taxes  (21,266)  2,062   (42,788)  10,678 
Income tax (benefit) expense  (8,642)  171   (17,929)  1,287 
             
(Loss) income from continuing operations  (12,624)  1,891   (24,859)  9,391 
Income from discontinued operations, net of taxes  2,163   878   3,895   8,793 
             
Net (loss) income  (10,461)  2,769   (20,964)  18,184 
Less: Net income attributable to noncontrolling interest  (2,355)  (2,273)  (5,718)  (9,860)
             
Net (loss) income attributable to MedCath Corporation $(12,816) $496  $(26,682) $8,324 
             
                 
Amounts attributable to MedCath Corporation common stockholders:                
(Loss) income from continuing operations, net of taxes $(14,155) $23  $(29,246) $1,708 
Income from discontinued operations, net of taxes  1,339   473   2,564   6,616 
             
Net (loss) income $(12,816) $496  $(26,682) $8,324 
             
                 
(Loss) earnings per share, basic                
(Loss) income from continuing operations attributable to MedCath Corporation common stockholders $(0.71) $  $(1.48) $0.09 
Income from discontinued operations attributable to MedCath Corporation common stockholders  0.07   0.03   0.13   0.33 
             
(Loss) earnings per share, basic $(0.64) $0.03  $(1.35) $0.42 
             
                 
(Loss) earnings per share, diluted                
(Loss) income from continuing operations attributable to MedCath Corporation common stockholders $(0.71) $  $(1.48) $0.09 
Income from discontinued operations attributable to MedCath Corporation common stockholders  0.07   0.03   0.13   0.33 
             
(Loss) earnings per share, diluted $(0.64) $0.03  $(1.35) $0.42 
             
                 
Weighted average number of shares, basic  19,897   19,733   19,823   19,665 
Dilutive effect of stock options and restricted stock           56 
             
Weighted average number of shares, diluted  19,897   19,733   19,823   19,721 
             
See notes to unaudited consolidated financial statements.

2


MEDCATH CORPORATION
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(In thousands)

(Unaudited)
                                         
                                      Redeemable 
                  Accumulated                  Noncontrolling 
                  Other              Total  Interest 
  Common Stock  Paid-in  Accumulated  Comprehensive  Treasury Stock  Noncontrolling  Equity  (Temporary 
  Shares  Par Value  Capital  Deficit  Loss  Shares  Amount  Interest  (Permanent)  Equity) 
                                         
Balance, September 30, 2009  22,105  $216  $455,259  $(91,420) $(360)  1,954  $(44,797) $18,184  $337,082  $7,448 
Stock awards, including cancelations and income tax benefit  374      1,979                  1,979    
Tax withholdings for vested restricted stock awards  (32)     (293)                 (293)   
Distributions to noncontrolling interest                       (14,005)  (14,005)  (3,560)
Acquisitions and other transactions impacting noncontrolling interest                       11   11   (43)
Sale of equity interest        113               27   140    
Comprehensive loss:                                        
Net loss           (26,682)           3,468   (23,214)  2,250 
Change in fair value of interest rate swap, net of income tax benefit (*)              (35)           (35)   
                               
Total comprehensive loss                                  (23,249)  2,250 
                               
Balance, June 30, 2010  22,447  $216  $457,058  $(118,102) $(395)  1,954  $(44,797) $7,685  $301,665  $6,095 
                               
(*)Tax benefits were $23 for the nine months ended June 30, 2010.
See notes to unaudited consolidated financial statements.

3


MEDCATH CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
         
  Three Months Ended December 31, 
  2010  2009 
         
Net revenue $88,900  $87,830 
Operating expenses:        
Personnel expense  32,454   31,636 
Medical supplies expense  19,222   22,107 
Bad debt expense  9,709   7,506 
Other operating expenses  24,116   22,344 
Pre-opening expenses     866 
Depreciation  4,887   5,938 
Loss on disposal of property, equipment and other assets  93   96 
       
Total operating expenses  90,481   90,493 
       
Loss from operations  (1,581)  (2,663)
Other income (expenses):        
Interest expense  (1,082)  (945)
Interest and other income  489   70 
Gain on sale of unconsolidated investees  15,391    
Equity in net earnings of unconsolidated affiliates  602   1,516 
       
Total other income (expense), net  15,400   641 
       
Income (loss) from continuing operations before income taxes  13,819   (2,022)
Income tax expense (benefit)  4,482   (1,337)
       
Income (loss) from continuing operations  9,337   (685)
Income (loss) from discontinued operations, net of taxes  39,128   (1,130)
       
Net income (loss)  48,465   (1,815)
Less: Net income attributable to noncontrolling interest  (11,426)  (841)
       
Net income (loss) attributable to MedCath Corporation $37,039  $(2,656)
       
         
Amounts attributable to MedCath Corporation common stockholders:        
Income (loss) from continuing operations, net of taxes $7,162  $(1,902)
Income (loss) from discontinued operations, net of taxes  29,877   (754)
       
Net income (loss) $37,039  $(2,656)
       
         
Earnings (loss) per share, basic        
Income (loss) from continuing operations attributable to MedCath Corporation common stockholders $0.36  $(0.09)
Income (loss) from discontinued operations attributable to MedCath Corporation common stockholders  1.50   (0.04)
       
Earnings (loss) per share, basic $1.86  $(0.13)
       
         
Earnings (loss) per share, diluted        
Income (loss) from continuing operations attributable to MedCath Corporation common stockholders $0.36  $(0.09)
Income (loss) from discontinued operations attributable to MedCath Corporation common stockholders  1.50   (0.04)
       
Earnings (loss) per share, diluted $1.86  $(0.13)
       
         
Weighted average number of shares, basic  19,943   19,743 
Dilutive effect of stock options and restricted stock  4    
       
Weighted average number of shares, diluted  19,947   19,743 
       
See notes to unaudited consolidated financial statements.

4


MEDCATH CORPORATION
CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(In thousands)
(Unaudited)
                                         
                                      Redeemable 
                  Accumulated                  Noncontrolling 
                  Other              Total  Interest 
  Common Stock  Paid-in  Accumulated  Comprehensive  Treasury Stock  Noncontrolling  Equity  (Temporary 
  Shares  Par Value  Capital  Deficit  Loss  Shares  Amount  Interest  (Permanent)  Equity) 
                                         
Balance, September 30, 2010  22,424  $216  $457,725  $(139,791) $(444)  1,954  $(44,797) $9,561  $282,470  $11,534 
Share based compensation        1,932                  1,932    
Tax withholdings for vested restricted stock awards  (162)     (1,705)                 (1,705)   
Distributions to noncontrolling interest                       (7,568)  (7,568)  (3,560)
Other transactions impacting noncontrolling interest                        45   45   45 
Exercise of call of noncontrolling interest                             (5,700)
Comprehensive loss:                                        
Net income           37,039            7,933   44,972   3,493 
Reclassification of amounts included in net income, net of tax benefit (*)              444            444    
                                       
Total comprehensive income                                  45,416   3,493 
                               
Balance, December 31, 2010  22,262  $216  $457,952  $(102,752) $   1,954  $(44,797) $9,971  $320,590  $5,812 
                               
(*)Tax expense was $286 for the quarter ended December 31, 2010.
See notes to unaudited consolidated financial statements.

5


MEDCATH CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
                
 Nine Months Ended June 30,  Three Months Ended December 31, 
 2010 2009  2010 2009 
Net (loss) income $(20,964) $18,184 
Net income (loss) $48,465 $(1,815)
Adjustments to reconcile net income to net cash provided by operating activities:  
Income from discontinued operations, net of taxes  (3,895)  (8,793)
(Income) loss from discontinued operations, net of taxes  (39,128) 1,130 
Bad debt expense 36,241 28,798  9,709 7,506 
Depreciation 23,054 19,179  4,887 5,938 
Amortization 24 24 
Gain on sale of unconsolidated investees  (15,391)  
Loss on disposal of property, equipment and other assets 39 127  93 96 
Share-based compensation expense 2,380 2,068  1,932 608 
Loss on early extinguishment of debt  6,702 
Amortization of loan acquisition costs 745 774  313 252 
Impairment of property and equipment 42,761  
Equity in earnings of unconsolidated affiliates, net of distributions received 3,259 1,777   (84) 6,217 
Deferred income taxes  (14,966) 58  1,085  (103)
Change in assets and liabilities that relate to operations:  
Accounts receivable  (38,557)  (22,427)  (10,693)  (12,106)
Medical supplies  (429)  (2,173)  (94)  (73)
Prepaid and other assets  (1,379)  (2,230) 2,266  (3,088)
Accounts payable and accrued liabilities  (3,526) 3,597   (2,825)  (2,523)
          
Net cash provided by operating activities of continuing operations 24,787 45,665  535 2,039 
Net cash provided by operating activities of discontinued operations 6,394 8,163 
Net cash (used in) provided by operating activities of discontinued operations  (5,131) 1,496 
          
Net cash provided by operating activities 31,181 53,828 
Net cash (used in) provided by operating activities  (4,596) 3,535 
  
Investing activities:  
Purchases of property and equipment  (16,842)  (68,038)  (157)  (7,532)
Proceeds from sale of property and equipment 110 836  418 70 
Sale of interest in equity method investment 436  
Proceeds from sale of unconsolidated affiliates 31,851  
          
Net cash used in investing activities of continuing operations  (16,296)  (67,202)
Net cash (used in) provided by investing activities of discontinued operations  (1,044) 2,554 
Net cash provided by (used in) investing activities of continuing operations 32,112  (7,462)
Net cash provided by (used in) investing activities of discontinued operations 194,616  (1,774)
          
Net cash used in investing activities  (17,340)  (64,648)
Net cash provided by (used in) investing activities 226,728  (9,236)
  
Financing activities:  
Proceeds from long-term debt  83,479 
Repayments of long-term debt  (16,678)  (115,515)  (7,662)  (5,000)
Repayments of obligations under capital leases  (1,381)  (827)  (614)  (454)
Distributions to noncontrolling interest  (9,334)  (10,312)  (4,504)  (6,924)
Investment by noncontrolling interest 109    153 
Sale of equity interest in subsidiary 140    140 
Proceeds from the exercise of stock options  77 
Tax withholding of vested restricted stock awards  (293)    (153)  (253)
          
Net cash used in financing activities of continuing operations  (27,437)  (43,098)  (12,933)  (12,338)
Net cash used in financing activities of discontinued operations  (9,063)  (5,241)
Net cash provided by financing activities of discontinued operations  (52,327)  (9,083)
          
Net cash used in financing activities  (36,500)  (48,339)  (65,260)  (21,421)
          
  
Net decrease in cash and cash equivalents  (22,659)  (59,159)
Net increase (decrease) in cash and cash equivalents 156,872  (27,122)
Cash and cash equivalents:  
Beginning of period 61,701 112,068  47,030 61,701 
          
End of period $39,042 $52,909  $203,902 $34,579 
          
  
Cash and cash equivalents of continuing operations 27,396 42,725  158,475 20,249 
Cash and cash equivalents of discontinued operations 11,646 10,184  45,427 14,330 
See notes to unaudited consolidated financial statements

46


MEDCATH CORPORATION
MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
1. Business and Basis of Presentation
     MedCath Corporation (the “Company”) primarily focuses on providing high acuity services, predominantlyincluding the diagnosis and treatment of cardiovascular disease. The Company owns and operates hospitals in partnership with physicians, mostphysicians. As of whom are cardiologistsDecember 31, 2010, the Company had ownership interests in and operated six hospitals, including five in which the Company owned a majority interest.
     As noted below under “Our Strategic Options Review Process”during the quarter ended December 31, 2010, the Company sold three of its majority owned hospitals that were classified as discontinued operations and its equity interest in one of its minority owned hospitals. As a result, the Company currently owns interests in six hospitals. Each of the Company’s majority-owned hospitals is a freestanding, licensed general acute care hospital that provides a wide range of health services with a majority focus on cardiovascular surgeons. While eachcare. Each of the Company’s hospitals (collectively, the “Hospital Division”) is licensed ashas a general acute care hospital, the Company focuses on serving the unique needs of patients suffering from cardiovascular disease. As of June 30, 2010, the Company and its physician partners24-hour emergency room staffed by emergency department physicians. The Company’s six hospitals that currently comprise continuing operations have an ownership interest in and currently operate ten hospitals in seven states, with a total of 825533 licensed beds 58 of whichand are related to the Heart Hospital of Austin (“HHA”), whose assets, liabilities,located in five states: Arkansas, California, Louisiana, New Mexico, and operations are included within discontinued operations. See Note 3 for further discussion related to the divestiture of HHA.
     In addition to its hospitals, the Company provides cardiovascular care services in diagnostic and therapeutic facilities in various locations and through mobile cardiac catheterization laboratories and also provides management services to non owned facilities (the “MedCath Partners Division”). The Company also provides consulting and management services tailored primarily to cardiologists and cardiovascular surgeons, which is included in Corporate and other.Texas.
     The Company accounts for all but twoone of its owned and operated hospitals as consolidated subsidiaries. The Company owns a noncontrolling interest in the Avera Heart Hospital of South Dakota and Harlingen Medical Center as of June 30,December 31, 2010. Therefore, the Company is unable to consolidate these hospitals’this hospital’s results of operations and financial position, but rather is required to account for its noncontrolling interestsinterest in these hospitalsthis hospital as equity method investments.an equity-method investment.
     In addition to the hospitals, the Company currently owns and/or manages seven cardiac diagnostic and therapeutic facilities. Six of these facilities are located at hospitals operated by other parties. These facilities offer invasive diagnostic and, in some cases, therapeutic procedures. The Company also operates two mobile cardiac catheterization laboratories which operate on set routes and offer only diagnostic procedures. The Company refers to its diagnostics division as “MedCath Partners.”
     During fiscal 2010 and fiscal 2011, the Company entered into definitive agreements to sell its interests in Arizona Heart Hospital (“AzHH”), Heart Hospital of Austin (“HHA”) and TexSan Heart Hospital (“TexSan”) whose assets, liabilities, and operations are included within discontinued operations. AzHH, HHA and TexSan were sold on October 1, 2010, November 1, 2010 and December 31, 2010, respectively. The results of operations of these entities are reported as discontinued operations for all periods presented. See Note 3.
Our Strategic Options Review Process
     On March 1, 2010, the Company’sCompany announced that its Board of Directors decided to beginhad formed a strategic alternatives review (the “Strategic Alternatives Review”)Strategic Options Committee to consider the sale either of either the CompanyCompany’s equity or the sale of its individual hospitals and other assets. The Strategic Alternatives Review process is continuing. The Company cannot provide any assurance regarding the result ofretained Navigant Capital Advisors as its financial advisor to assist in this process.
Basis Since announcing the exploration of Presentation— Effective Octoberstrategic alternatives on March 1, 2009,2010, the Company adopted a new accounting standard which establishes accounting and reporting standards pertaining to ownership interests in subsidiaries held by parties other than the parent, the amount of net income attributable to the parent and to the noncontrolling interests, changes in a parent’s ownership interest and the valuation of any retained noncontrolling equity investment when a subsidiary is deconsolidated. This new accounting standard also establishes disclosure requirements that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. This new accounting standard generally requires the Company to clearly identify and present ownership interests in subsidiaries held by parties other than the Company in the consolidated financial statements within the equity section but separate from the Company’s equity. However, in instances in which certain redemption features that are not solely within the control of the issuer are present, classification of noncontrolling interests outside of permanent equity is required. It also requires the amounts of consolidated net income attributable to the Company and to the noncontrolling interests to be clearly identified and presented on the face of the consolidated statements of operations; changes in ownership interests to be accounted for as equity transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary to be measured at fair value. The implementation of this accounting standard results in the cash flow impact of certainhas completed several transactions, with noncontrolling interests being classified within financing activities. Such treatment is consistent with the view that under this new accounting standard, transactions between the Company and noncontrolling interests are considered to be equity transactions. The adoption of this new accounting standard has been applied retrospectively for all periods presented.including:
     Upon the occurrence of certain fundamental regulatory changes, the Company could be obligated, under the terms of certain of its investees’ operating agreements, to purchase some or all of the noncontrolling interests related to certain of the Company’s subsidiaries. While the Company believes that the likelihood of a change in current law that would trigger such purchases was remote as of June 30, 2010, the occurrence of such regulatory changes is outside the control of the Company. As a result, these noncontrolling interests that are subject to this redemption feature are not included as part of the Company’s equity and are carried as redeemable noncontrolling interests in equity of consolidated subsidiaries on the Company’s consolidated balance sheets.
The disposition of AzHH in which the Company sold the majority of the hospital’s assets to Vanguard Health Systems for $32.0 million, plus retained working capital. The transaction was completed effective October 1, 2010.
The disposition of the Company’s wholly owned subsidiary that held 33.3% ownership of Avera Heart Hospital of South Dakota (Sioux Falls, SD) to Avera McKennan for $20.0 million, plus a percentage of the hospital’s available cash. The transaction was completed October 1, 2010.
The disposition of HHA in which the Company and the physician owners sold substantially all of the hospital’s assets to St. David’s Healthcare Partnership L.P. for approximately $83.8 million, plus retained working capital. The transaction was completed effective November 1, 2010.
The disposition of the Company’s approximate 27.0% ownership interest in Southwest Arizona Heart and Vascular, LLC (Yuma, AZ) to the joint venture’s physician partners for $7.0 million. The transaction was completed effective November 1, 2010.
The disposition of TexSan in which the Company sold the majority of the hospital’s assets to Methodist Healthcare System of San Antonio for $76.25 million, plus an adjustment for retained working capital. The transaction was completed effective December 31, 2010.

57


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     Profits and losses are allocated to the noncontrolling interest in the Company’s subsidiaries in proportion to their ownership percentages and reflected in the aggregate as net income attributable to noncontrolling interests. The physician partnersBasis of the Company’s subsidiaries typically are organized as general partnerships, limited partnerships or limited liability companies that are not subject to federal income tax. Each physician partner shares in the pre-tax earnings of the subsidiary in which it is a partner. Accordingly, the income or loss attributable to noncontrolling interests in each of the Company’s subsidiaries are generally determined on a pre-tax basis. In accordance with this new accounting standard, total net income attributable to noncontrolling interests are presented after net (loss) income.
Presentation The Company’s unaudited interim consolidated financial statements as of June 30,December 31, 2010 and for the three and nine months ended June 30,December 31, 2010 and 2009 have been prepared in accordance with accounting principles generally accepted in the United States of America hereafter, (“generally accepted accounting principles”) and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). These unaudited interim consolidated financial statements reflect, in the opinion of management, all material adjustments necessary to fairly state the results of operations and financial position for the periods presented. All intercompany transactions and balances have been eliminated.
     Certain information and disclosures normally included in the notes to consolidated financial statements have been condensed or omitted as permitted by the rules and regulations of the SEC, although the Company believes the disclosures are adequate to make the information presented not misleading. The unaudited interim consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2009.2010. During the ninethree months ended June 30,December 31, 2010, the Company has not made any material changes in the selection or application of its critical accounting policies that were set forth in its Annual Report on Form 10-K for the fiscal year ended September 30, 2009.
     The Company has evaluated the provisions of the Patient Protection and Affordable Care Act, as enacted on March 23, 2010 and the Health Care and Education Reconciliation Act of 2010 as enacted on March 30, 2010 (collectively the “Health Reform Laws”). The Company is unable to predict at this time the full impact of the Health Reform Laws on the Company and its consolidated financial statements.
Long-Lived Assets— Long-lived assets, such as property, and equipment, and purchased intangible assets subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by an asset to the carrying value of the asset. If the carrying value of the long-lived asset is not recoverable on an undiscounted cash flow basis, impairment is recognized to the extent that the carrying value exceeds its fair value. Fair value is determined through various valuation techniques including, but not limited to, discounted cash flow models, quoted market values, and third-party independent appraisals. The determination of whether or not long-lived assets have become impaired involves a significant level of judgment in the assumptions underlying the approach used to determine the estimated future cash flows expected to result from the use of those assets. Changes in the Company’s strategy, assumptions and/or market conditions could significantly impact these judgments and require adjustments to recorded amounts of long-lived assets.
     Due to a decline in operating performance at certain hospitals during fiscal 2009, the Company performed impairment tests utilizing undiscounted cash flows as of September 30, 2009. The results of those tests indicated that no impairment existed as of that date. Due to continued declines in the operating performance of certain hospitals during the first six months of fiscal 2010, the Company performed impairment tests using undiscounted cash flows to determine if the carrying value of these hospital’s long-lived assets were recoverable as of March 31, 2010. The results indicated the current carrying value of the assets at certain hospitals were not recoverable. The Company compared the fair value of those assets to their respective carrying values in order to determine the amount of impairment. The Company recognized impairment charges based on the amount each group of assets’ carrying value exceeded its fair value. The Company’s fair value estimates were derived by management using independent appraisals, established market values of comparable assets, and internal estimates of future discounted net cash flows.

6


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     During the three months ended June 30, 2010, additional information became available relative to the fair market value of certain assets as a result of the Company’s ongoing Strategic Alternatives Review. As a result, it was determined that additional impairment may have occurred related to assets within its Hospital Division and Corporate and other. The Company performed impairment tests using undiscounted cash flows to determine if the carrying value of the long-lived assets were recoverable as of June 30, 2010. The results indicated the current carrying value of the assets were not recoverable. The Company compared the fair value of those assets to their respective carrying values in order to determine the amount of impairment. The Company recognized an impairment charge based on the amount each group of assets’ carrying value exceeded its fair value. The Company’s fair value estimates were derived by management from independent third party market offers and internal estimates of future discounted net cash flows.
     These fair value estimates could change by material amounts in subsequent periods. Many factors and assumptions can impact the estimates, including the future financial results of these hospitals, how the hospitals are operated in the future, changes in health care industry trends and regulations, the impact of future decisions relative to the Company’s Strategic Alternatives Review, and the impact on the nature and timing of the ultimate disposition of the assets. The impairments recognized do not include the costs of closing the hospitals or other future operating costs, which could be substantial. Accordingly, the ultimate net cash realized from the hospitals could be significantly less than their impaired value. See Note 13 for the impairment charges recorded to property and equipment and Note 15 for further discussions as to the Company’s determination of fair value.
2. Recent Accounting Pronouncements
     The following is a summary of new accounting pronouncements that have been adopted or that may apply to the Company.
     Recently Adopted Accounting Pronouncements:Pronouncements
     In December 2007, the FASB issued a new accounting standard that establishes accounting and reporting standards pertaining to ownership interests in subsidiaries held by parties other than the parent, the amount of net income attributable to the parent and to the noncontrolling interests, changes in a parent’s ownership interest, and the valuation of any retained noncontrolling equity investment when a subsidiary is deconsolidated. This new accounting standard also establishes disclosure requirements that clearly identify and distinguish between the interests of the parent and the interests of the noncontrolling owners. The Company adopted this new standard onOn October 1, 2009. Upon adoption, a portion of noncontrolling interests was reclassified to a separate component of total equity within our consolidated balance sheets. See Note 1Business and Basis of Presentationabove for a more detailed discussion regarding the adoption of this new standard.
     In April 2008, the FASB issued a new accounting standard which amends the list of factors an entity should consider in developing renewal or extension assumptions used in determining the useful life of recognized intangible assets. The new accounting standard applies to intangible assets that are acquired individually or with a group of other assets and intangible assets acquired in both business combinations and asset acquisitions. The Company adopted this new standard on October 1, 2009 with no impact to its consolidated financial statements.
     Effective the first quarter of fiscal 2009,2010, the Company adopted a new accounting standard issued by the FASB that defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measures required under other accounting pronouncements, but does not change existing guidance as to whether or not an instrument is carried at fair value. In February 2008, the FASB delayed the effective date of this new standard for all nonfinancial assets and liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis (at least annually). The Company elected to defer implementation of this standard until October 1, 2009 as it relates to the Company’s non-financial assets and non-financial liabilities that are not permitted or required to be measured at fair value on a recurring basis. The Company adopted this standard on October 1, 2009 with no impact to its consolidated financial statements.

7


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
Recent Accounting Pronouncements:
     In June 2009, the FASB issued a new accounting standard that amends the consolidation guidance that applies to variable interest entities (“VIE”). The amendments will significantly affect the overall consolidation analysis. The provisions of this new accounting standard revise the definition and consideration of VIEs, primary beneficiary, and triggering events in which a company must re-evaluate its conclusions as to the consolidation of an entity. This new accountingThe adoption of this standard did not have an impact on the Company’s consolidated financial statements.
Recent Accounting Pronouncements
     In August 2010, the FASB issued Accounting Standard Updates (“ASU”) 2010-24, “Health Care Entities (Topic 954): Presentation of Insurance Claims and Related Insurance Recoveries,” which clarifies that a health care entity should not net insurance recoveries against a related claim liability. The guidance provided in this ASU is effective as of the beginning of the first fiscal year beginning after NovemberDecember 15, 2009,2010, fiscal 20112012 for the Company. The Company is evaluating the potential impacts the adoption of this new standardASU will have on itsour consolidated financial statements.
3. Divestitures
     During     In August 2010, the Company entered intoFASB issued ASU 2010-23, “Health Care Entities (Topic 954): Measuring Charity Care for Disclosure,” which requires a definitive agreementcompany in the healthcare industry to sell substantially alluse its direct and indirect costs of providing charity care as the measurement basis for charity care disclosures. This ASU also requires additional disclosures of the assets, andmethod used to assign certainidentify such costs. The guidance provided in this ASU is effective for fiscal years beginning after December 15, 2010, fiscal 2012 for the Company. The adoption of the liabilities, of Arizona Heart Hospital, LLC for approximately $32.0 million. The transactionthis ASU is not expected to close after finalizationhave any impact on our consolidated financial position or results of certain closing conditions.operations.
3. Discontinued Operations
     During February 2010,As required under accounting principles generally accepted in the Company entered into an agreement to sell certain assets and liabilities of HHA for approximately $83.6 million. The sale is expected to close after all regulatory approvals are obtained. TheUnited States (“GAAP”), the Company has classified the results of operations of HHAthe following entities within income from discontinued operations, net of taxes forand the three and nine months ended June 30, 2010 and 2009. The assets and liabilities of HHAthese entities have been classified within current and non-current assets and current and long-term liabilities of discontinued operations on the consolidated balance sheets assheets.
     During November 2010, the Company entered into an agreement to sell substantially all of June 30,the assets of TexSan for $76.25 million, plus an adjustment for retained working capital. The transaction closed on December 31, 2010 with the Company retaining all accounts receivable and September 30, 2009.the hospital’s remaining liabilities. In addition, the Company acquired the partnership’s minority investors’ ownership in accordance with the terms of a call option agreement. See Note 7 for further discussion. The gain from this sale of $34.3 million has been included in income (loss) from discontinued operations for the three months ended December 31, 2010.
     During September 2009,2010, the MedCath Partners DivisionCompany entered into an agreement to sell its subsidiary that provided consulting and management services tailored primarily to cardiologists and cardiovascular surgeons. Such subsidiary’s operations had historically been included in the Corporate and other division. Such subsidiary was sold in October 2010 for an immaterial loss.

8


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     During August 2010, the Company entered into a definitive agreement to sell certain of the hospital assets and liabilities, plus certain net working capital of AzHH for $32.0 million and the assumption of capital leases of $0.3 million. The transaction closed on October 1, 2010 with the limited liability company which owned AzHH retaining all accounts receivable and the hospital’s remaining liabilities. As part of its assessment of long-lived assets in June 2010, the Company soldrecognized an impairment charge of $5.2 million based on its potential sales value of AzHH. Accordingly, the Company recognized a nominal gain on the sale for the three months ended December 31, 2010.
     During February 2010, the Company entered into an agreement to sell substantially all of the assets of Sun City Cardiac Center Associates (“Sun City”)HHA for $16.9$83.8 million plus retention of working capital to St. David’s Healthcare Partnership, L.P, which resulted in a gain of $3.2 million, net of taxes.$35.7 million. The Company has classified the results of operations of Sun City within income from discontinued operations, net of taxes for the three and nine months ended June 30, 2010 and 2009. The assets and liabilities of Sun City have been classified within current assets and current liabilities of discontinued operationstransaction closed on the consolidated balance sheets as of June 30, 2010 and September 30, 2009.
     During December 2008, the MedCath Partners Division of the Company sold its entire interest in Cape Cod Cardiology Services, LLC (“Cape Cod”) for $6.9 million, which resulted in a gain of $4.0 million, net of taxes. The Company has classified the results of operations of Cape Cod within income from discontinued operations, net of taxes for the three and nine months ended June 30, 2009.November 1, 2010.
     During May 2008, the Hospital Division of the Company sold the net assets of Dayton Heart Hospital (“DHH”). The Company has classified the results to Good Samaritan Hospital pursuant to a definitive agreement. As of operations related to the remaining assetsDecember 31, 2010 and liabilities associated with DHH within income from discontinued operations, net of taxes for the three and nine months ended JuneSeptember 30, 2010, the Company had reserved $10.0 million and 2009. The assets and liabilities of$9.8 million, respectively, for Medicare outlier payments received by DHH have been classified within current assets andduring the year ended September 30, 2004, which are included in current liabilities of discontinued operations onin the consolidated balance sheets assheets.
     The Company has entered into transition services agreements with the buyers of June 30, 2010 and September 30, 2009.certain of its sold assets that extend into fiscal 2011. As a result, the Company entered into a Managed Services Agreement with McKesson Technologies, Inc. (“McKesson”) whereby McKesson would employ the majority of the Company’s information technology employees effective November 1, 2010.
     The results of operations and the assets and liabilities of discontinued operations included in the consolidated statements of operations and consolidated balance sheets are as follows:
                 
  Three Months Ended June 30,  Nine Months Ended June 30, 
  2010  2009  2010  2009 
                 
Net revenue $23,415  $26,797  $71,482  $84,634 
Gain from sale of Cape Cod           6,640 
Income before income taxes  3,070   1,182   5,567   13,071 
Income tax expense  907   304   1,672   4,278 
             
Net income before noncontrolling interest  2,163   878   3,895   8,793 
Less: Net income attributable to noncontrolling interest  (824)  (405)  (1,331)  (2,177)
             
Net income attributable to MedCath Corporation $1,339  $473  $2,564  $6,616 
             

8


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
         
  Three Months Ended December 31, 
  2010  2009 
         
Net revenue $22,004  $59,386 
Gain (loss) from dispositions, net  69,903    
Loss on early termination of debt  (11,130)   
Income (loss) before income taxes  57,762   (1,423)
Income tax (benefit) expense  18,634   (293)
       
Net income (loss)  39,128   (1,130)
Less: Net (income) loss attributable to noncontrolling interest  (9,251)  376 
       
Net income (loss) attributable to MedCath Corporation $29,877  $(754)
       
         
  June 30,  September 30, 
  2010  2009 
         
Cash and cash equivalents $11,646  $29,818 
Accounts receivable, net  10,182   11,821 
Other current assets  4,344   3,339 
       
Current assets of discontinued operations $26,172  $44,978 
       
         
Property and equipment, net $43,612  $44,532 
Other assets  3,129   2,817 
       
Long-term assets of discontinued operations $46,741  $47,349 
       
         
Accounts payable $14,369  $14,956 
Accrued liabilities  4,484   4,820 
Current portion of long-term debt and obligations under capital leases  209   56 
       
Current liabilities of discontinued operations $19,062  $19,832 
       
         
Long-term debt and obligations under capital leases $35,117  $35,359 
Other long-term obligations  755   362 
       
Long-term liabilities of discontinued operations $35,872  $35,721 
       
4. Accounts Receivable
Accounts receivable, net, consists of the following:
         
  June 30,  September 30, 
  2010  2009 
Receivables, principally from patients and third-party payors $140,281  $126,577 
Receivables, principally from billings to hospitals for various cardiovascular procedures  1,368   1,494 
Amounts due under management contracts  217   228 
Other  5,186   5,503 
       
   147,052   133,802 
Less allowance for doubtful accounts  (85,822)  (74,889)
       
Accounts receivable, net $61,230  $58,913 
       
         
  December 31,  September 30, 
  2010  2010 
         
Cash and cash equivalents $45,427  $13,889 
Accounts receivable, net  11,478   23,597 
Other current assets  440   10,434 
       
Current assets of discontinued operations $57,345  $47,920 
       
         
Property and equipment, net $  $115,670 
Other assets  1,232   3,620 
       
Long-term assets of discontinued operations $1,232  $119,290 
       
         
Accounts payable $14,003  $25,379 
Accrued liabilities and current portion of obligations under capital leases  3,011   9,665 
       
Current liabilities of discontinued operations $17,014  $35,044 
       
         
Long-term debt and obligations under capital leases $  $35,302 
Other long-term obligations     666 
       
Long-term liabilities of discontinued operations $  $35,968 
       

9


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     Included in the Company’s discontinued liabilities as of September 30, 2010 is a Real Estate Investment Trust Loan (the “REIT Loan”) aggregating $34.6 million. Borrowings under this REIT Loan were collateralized by a pledge of the Company’s interest in the related hospital’s property, equipment and certain other assets. The REIT Loan required monthly, interest-only payments for ten years, at which time the loan was due in full, maturing January 2016. The interest rate on this loan was 8 1/2%. Upon the disposition of the Company’s interest in the related hospital, the REIT Loan was repaid in full in November 2010 and the Company incurred an $11.1 million prepayment penalty, which is included in income (loss) from discontinued operations.
     Included in discontinued operations are certain liabilities that the Company has retained upon the disposition of the related entity. Because the Company’s hospitals are organized as partnerships, upon disposition of the related operations, assets and certain liabilities, the partnerships are responsible for the resolution of outstanding payables, remaining obligations, including those related to cost reports, medical malpractice and other obligations and wind down of the respective tax filings of the partnership. The partnerships are also responsible for any unknown liabilities that may arise. The Company has reported all known obligations in its consolidated balance sheets as of December 31, 2010 and September 30, 2010.
4. Accounts Receivable
Accounts receivable, net, consists of the following:
         
  December 31,  September 30, 
  2010  2010 
Receivables, principally from patients and third-party payors $106,804  $103,314 
Receivables, principally from billings to hospitals for various cardiovascular procedures  1,428   1,027 
Other  2,975   2,555 
       
   111,207   106,896 
Less allowance for doubtful accounts  (66,412)  (63,085)
       
Accounts receivable, net $44,795  $43,811 
       
5. Equity Investments in Affiliates
     The Company’s determination of the appropriate consolidation method to follow with respect to investments in affiliates is based on the amount of control the Company has and the ownership level in the underlying entity. Investments in entities that the Company does not control, but over whose operations the Company has the ability to exercise significant influence (including investments where the Company has a less than 20% ownership) are accounted for under the equity method. The Company additionally considers if it is the primary beneficiary of (and therefore should consolidate) any entity whose operations the Company does not control. At December 31, 2010, all of the Company’s investments in unconsolidated affiliates are accounted for using the equity method. At December 31, 2010, the Company owns a noncontrolling interestsinterest in the Avera Heart Hospital of South Dakota, Harlingen Medical Center and certain diagnostic ventures and partnerships, for which the Company neither has substantive control over the ventures nor is the primary beneficiary. Therefore,These investments are included in Other Assets on the consolidated balance sheets.
     On October 1, 2010, the Company does not consolidatesold its interest in Avera Heart Hospital of South Dakota for $25.1 million to Avera McKennan whereby Avera McKennan purchased a MedCath subsidiary which was the resultsindirect owner of operationsa one-third ownership interest and financial positionwhich held management rights in Avera Heart Hospital of these entities, but rather accountsSouth Dakota. Prior to its disposition, the Company had accounted for its noncontrollinginvestment in Avera Heart Hospital of South Dakota using the equity method of accounting. The Company recognized a gain on the disposition of $15.4 million. The Company’s investment in Avera Heart Hospital of South Dakota reflected its proportionate share of an interest rate swap that the hospital had entered into. The cumulative unrealized loss of $0.5 million (net of taxes) was reclassified from Other Comprehensive Income as part of the gain in connection with the sale of the Company’s ownership interest.
     On November 1, 2010, the Company sold its equity interest in Southwest Arizona Heart and Vascular Center, LLC for $7.0 million. The Company recognized a write down of its investment in the hospitals and other ventures as equity method investments.
     During the second and third quartersfourth quarter of fiscal 2010 the MedCath Partners Division sold its entire interest in two ventures, resulting in an immaterial loss.
     The following tables represent summarized combined financial information ofto record the Company’s unconsolidated affiliatesinvestment in such business at its net realizable value expected from the sale proceeds. Prior to its disposition, the Company had accounted for underits investment in Southwest Arizona Heart and Vascular Center, LLC using the equity method:
                 
  Three Months Ended June 30, Nine Months Ended June 30,
  2010 2009 2010 2009
                 
Net revenue $56,368  $56,196  $167,199  $171,405 
Income from operations $11,161  $12,070  $34,102  $37,118 
Net income $8,871  $9,750  $27,280  $30,326 
         
  June 30, September 30,
  2010 2009
         
Current assets $56,270  $68,174 
Long-term assets $146,207  $148,993 
Current liabilities $23,547  $25,770 
Long-term liabilities $122,869  $122,629 
6. Long-Term Debt
     Long-term debt consistsmethod of the following:
         
  June 30,  September 30, 
  2010  2009 
         
Credit Facility $69,375  $80,000 
Notes payable to various lenders     6,054 
       
   69,375   86,054 
Less current portion  (13,125)  (19,491)
       
Long-term debt $56,250  $66,563 
       
accounting.

10


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     The following tables represent summarized combined financial information of the Company’s unconsolidated affiliates accounted for under the equity method (For those entities in which the Company has disposed of its interest, the operating activities have been included through their respective date of disposition):
         
  Three Months Ended December 31,
  2010 2009
         
Net revenue $35,968  $53,326 
Income from operations $6,425  $8,073 
Net income $4,440  $5,777 
         
  December 31, September 30,
  2010 2010
         
Current assets $33,063  $58,690 
Long-term assets $79,092  $144,402 
Current liabilities $14,325  $23,922 
Long-term liabilities $98,848  $121,524 
6. Long-Term Debt
     Long-term debt consists of the following:
         
  December 31,  September 30, 
  2010  2010 
         
Amended Credit Facility  58,901   66,563 
Less current portion  (58,901)  (14,063)
       
Long-term debt $  $52,500 
       
Senior Secured Credit FacilityDuring November 2008, the Company amended and restated its then outstanding senior secured credit facility (the “Credit“Amended Credit Facility”). The Amended Credit Facility provides for a three-year term loan facility in the amount of $75.0 million (the “Term Loan”) and a revolving credit facility in the amount of $85.0 million (the “Revolver”), which includes a $25.0 million sub-limit for the issuance of stand-by and commercial letters of credit (of which $1.7 million were outstanding as of December 31, 2010 and September 30, 2010) and a $10.0 million sub-limit for swing-line loans. At the request of the Company and approval from its lenders, the aggregate amount available under the Amended Credit Facility may be increased by an amount up to $50.0 million. Borrowings under the Amended Credit Facility, excluding swing-line loans, bear interest per annum at a rate equal to the sum of LIBOR plus anthe applicable margin or the alternate base rate plus anthe applicable margin. At December 31, 2010 the Term Loan bore interest at 3.26%. The $58.9 million and $66.6 million outstanding under the Amended Credit Facility at December 31, 2010 and September 30, 2010, respectively, related to the Term Loan. No amounts were outstanding under the Revolver as of December 31, 2010 and September 30, 2010.
     The Amended Credit Facility iscontinues to be guaranteed jointly and severally by the Company and certain of the Company’s existing and future, direct and indirect, wholly owned subsidiaries and is secured by a first priority perfected security interest in all of the capital stock or other ownership interests owned by the Company and subsidiary guarantors in each of their subsidiaries, and, subject to certain exceptions in the Amended Credit Facility, all other present and future assets and properties of the Company and the subsidiary guarantors and all intercompany notes.
     The Amended Credit Facility requires compliance with certain financial covenants including a consolidated senior secured leverage ratio test, a consolidated fixed charge coverage ratio test and a consolidated total leverage ratio test. The Amended Credit Facility also contains customary restrictions on, among other things, the Company and subsidiaries’ ability to incur liens; engage in mergers, consolidations and sales of assets; incur debt; declare dividends; redeem stock and repurchase, redeem and/or repay other debt; make loans, advances and investments and acquisitions; and enter into transactions with affiliates.
     The Amended Credit Facility contains events of default, including cross-defaults to certain indebtedness, change of control events, and other events of default customary for syndicated commercial credit facilities. Upon the occurrence of an event of default, the Company could be required to immediately repay all outstanding amounts under the Amended Credit Facility.

11


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     The Company is required to make mandatory prepayments of principal in specified amounts upon the occurrence of certain events identified in the Amended Credit Facility and is permitted to make voluntary prepayments of principal under the Amended Credit Facility. The Term Loan is subject to amortization of principal in quarterly installments, which began March 31, 2010. The maturity date of both the Term Loan and the Revolver is November 10, 2011.
     On August 13, 2010, the Company and its lenders amended and restated the Senior Secured Credit Facility (the “First Amendment”). The $69.4Company entered into the First Amendment to provide additional financial and liquidity flexibility in connection with its previously announced effort to explore strategic alternatives. The First Amendment contains modifications of certain financial covenants and other requirements of the Amended Credit Facility; including, but not limited to: modifications to certain definitions contained in the Amended Credit Facility, including the definitions of certain financial terms to permit additional add backs (such as an add back for charges and professional expenses incurred in connection with asset dispositions), subject to maximum amounts in certain cases, and to the multiple applied to certain of the financial metrics derived in accordance with such definitions, for certain financial covenant calculations; increasing the amount of permitted guarantees of indebtedness by $10 million; amending the asset dispositions covenant to permit additional asset dispositions subject to no events of default and require that any net cash proceeds from an asset disposition or series of dispositions in excess of $50 million from the date of the First Amendment be applied 50% to repay the outstanding Term Loan amounts under the Amended Credit Facility and 50% to repay amounts outstanding under the Credit Facility at June 30,Revolver or cash collateralize letters of credit to the extent outstanding and permanently reduce the Revolver by 50% of the net cash proceeds, which could shorten the term of the Revolver based on the amount of such permanent commitment reductions. In addition, any mandatory prepayments of the Revolver will also reduce the revolving credit commitment by a corresponding amount.
     In addition to the quarterly installment, during the three months ended December 31, 2010, relatedthe Company paid $4.8 million using net cash proceeds from asset dispositions. The Revolver including letters of credit will not be permitted to remain outstanding after the full repayment of the Term Loan. At JuneThe First Amendment also provides for a reduction in amount of the Revolver from $85 million to $59.5 million as of the date of the First Amendment. As noted under the terms of the First Amendment, the Revolver was further reduced to $54.4 million at December 31, 2010 for mandatory repayment of principal using net cash proceeds from asset dispositions. Under terms of the First Amendment, the fixed charge coverage ratio is not tested at September 30, 2010 or December 31, 2010, and will be retested at the Term Loan bore interest at 3.35%. The maximum availability under the Revolver is $85.0 million which was reduced by outstanding letters of credit totaling $1.7 million at June 30, 2010.fiscal quarter ending March 31, 2011 and subsequent fiscal quarters.
     DuringAs further noted in Note 14, the third quarter ended JuneCompany made an additional $20.6 million repayment of outstanding principal in January 2011.
Debt Covenants—As of December 31, 2010 and September 30, 2010, the Company repaidwas in compliance with all covenants governing its outstanding debt.
Interest Rate Swap— During the remaining $4.2year ended September 30, 2006 one of the hospitals in which the Company had a noncontrolling interest and accounted for under the equity method, entered into an interest rate swap for purposes of hedging variable interest payments on long term debt outstanding for that hospital. The interest rate swap is accounted for as a cash flow hedge by the hospital whereby changes in the fair value of the interest rate swap flow through comprehensive income of the hospital. The Company recorded its proportionate share of comprehensive income within stockholders’ equity in the consolidated balance sheets based on the Company’s ownership interest in that hospital. However, as noted in Note 5, the cumulative unrealized loss of $0.5 million note payable obligations to certain equipment lenders(net of taxes) was reclassified from Other Comprehensive Income as part of the gain in connection with the sale of the Company’s ownership interest on behalfOctober 1, 2010.
7. Contingencies and Commitments
Put and Call Options— During August 2010, the Company entered into a put/call agreement with the minority shareholders one of its consolidated subsidiary, TexSAn Heart Hospital.
     During December 2008,hospitals, whereby call and put options were added relative to the Company’s noncontrolling interest in the hospital. The call allowed the Company redeemed its outstanding 9 7/8% senior notes (the “Senior Notes”) issuedto acquire all of the noncontrolling interest in the hospital owned by MedCath Holdings Corp.,physician investors for the net amount of the physician investors’ unreturned capital contributions adjusted upward for any proportionate share of additional proceeds upon a wholly owned subsidiary ofdisposition transaction. The put allowed the Company’s noncontrolling shareholders in the hospital to put their shares to the Company for $111.2the net amount of the physician investors’ unreturned capital contributions. The noncontrolling shareholders’ recorded basis in their partnership interest was zero prior to the amendment of this agreement. Accordingly, the Company recognized a redeemable noncontrolling interest of $4.5 million ($2.9 million net of taxes) as of September 30, 2010. During December 2010, the Company exercised its call right and recognized additional redeemable noncontrolling interest of $2.2 million. Furthermore, upon exercise, the Company converted the outstanding balance of the noncontrolling interest in this partnership together with amounts due from the noncontrolling shareholders into a net obligation of $5.7 million, which is included in other accrued liabilities as of December 31, 2010.
     During September 2010, the paymentCompany entered into a call agreement with the minority shareholders of a repurchase premiumone of $5.0 million and accruedits hospitals whereby the Company may exercise the call right to purchase the noncontrolling interest of $4.2 million. The Senior Notes were redeemed through borrowings under the Credit Facility and available cash on hand. In additionowned by physician investors for an amount equal to the aforementioned repurchase premium,net amount of the Company incurred $2.0physician investors unreturned capital contributions ($2.7 million in expense related to the write-off of previously incurred financing costs associated with the Senior Notes. The repurchase premiumat December 31, 2010 and write off of previously incurred financing costs have been included in the consolidated statements of operations as loss on early extinguishment of debt for the nine months ended JuneSeptember 30, 2009.2010).

1112


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
Debt Covenants—At September 30, 2009, the Company was in violation of financial covenants under equipment loans at its consolidated subsidiary TexSAn Heart Hospital. Accordingly, the total outstanding balance for these loans of $6.1 million was included in the current portion of long-term debt and obligations under capital leases on the Company’s consolidated balance sheet. These loans were paid in-full as of June 30, 2010. As of June 30, 2010, the Company was in compliance with all covenants governing its outstanding debt.
Fair Value of Financial Instruments—The Company considers the carrying amounts of significant classes of financial instruments on the consolidated balance sheets to be reasonable estimates of fair value due either to their length to maturity or the existence of variable interest rates underlying such financial instruments that approximate prevailing market rates at June 30, 2010 and September 30, 2009. The estimated fair value of long-term debt, including the current portion, at June 30, 2010 was approximately $110.2 million ($40.8 million related to discontinued operations) as compared to a carrying value of $104.0 million ($34.6 million related to discontinued operations). At September 30, 2009, the estimated fair value of long-term debt, including the current portion, was approximately $127.6 million ($41.4 million related to discontinued operations) as compared to a carrying value of $121.4 million ($35.3 million related to discontinued operations). Fair value of the Company’s fixed rate debt was estimated using discontinued cash flow analyses, based on the Company’s current incremental borrowing rates for similar types of arrangements and market information. The fair value of the Company’s variable rate debt was determined to approximate its carrying value due to the underlying variable interest rates.
7. Contingencies and Commitments
     Contingencies —The Medicare and Medicaid programs are subject to statutory and regulatory changes, retroactive and prospective rate adjustments, administrative rulings, court decisions, executive orders and freezes and funding reductions, all of which may significantly affect the Company. In addition, reimbursement is generally subject to adjustment following audit by third party payors, including commercial payors as well as the fiscal intermediariescontractors who administer the Medicare program for the Centers for Medicare and Medicaid Services (“CMS”).
     Final determination of amounts due providers under the Medicare program often takes several years because of such audits, as well as resulting provider appeals and the application of technical reimbursement provisions. The Company believes that adequate provisions have been made for any adjustments that might result from these programs; however, due to the complexity of laws and regulations governing the Medicare and Medicaid programs, the manner in which they are interpreted and the other complexities involved in estimating net revenue, there is a possibility that recorded estimates will change by a material amount in the future.
     In 2005, the CMS began using recovery audit contractors (“RAC”) to detect Medicare overpayments not identified through existing claimclaims review mechanisms. RACs perform post-discharge audits of medical records to identify Medicare overpayments resulting from incorrect payment amounts, non-covered services, incorrectly coded services, and duplicate services. The CMS has given RACs the authority to look back at claims up to three years old, provided that the claim was paid on or after October 1, 2007. Claims identified as overpayments will be subject to the Medicare appeals process. The Health Care Reform Laws expanded the RAC program’s scope to include Medicaid claims by requiring all states to enter into contracts with RACs by December 31, 2010. The Company believes the claims for reimbursement submitted to the Medicare programand Medicaid programs by the Company’s facilities have been accurate, however the Company is unable to reasonably estimate what the potential result of future RAC audits or other reimbursement matters could be.

12


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     The Company is involved in various claims and legal actions in the ordinary course of business, including malpractice claims arising from services provided to patients that have been asserted by various claimants and additional claims that may be asserted for known incidents through June 30,December 31, 2010. These claims and legal actions are in various stages, and some may ultimately be brought to trial. Moreover, additional claims arising from services provided to patients in the past and other legal actions may be asserted in the future. The Company is protecting its interests in all such claims and actions and does not expect the ultimate resolution of these matters to have a material adverse impact on the Company’s consolidated financial position, results of operations or cash flows.
     During the prior fiscal year,years 2008 and 2007, the Company refunded certain reimbursements to CMS related to carotid artery stent procedures performed during prior fiscal years at two of the Company’s consolidated subsidiary hospitals. The U.S. Department of Justice (“DOJ”) initiated an investigation related to the Company’s return of these reimbursements. As a result of the DOJ’s investigation, the Company negotiated abegan negotiating settlement agreementagreements during the thirdsecond quarter of fiscal 2009 with the DOJ whereby the Company was expected to pay approximately $0.8 million to settle and obtain a releasereleases from any federal civil false claims liability related to the DOJ’s investigation. The DOJ allegations dodid not involve patient care, and relaterelated solely to whether the procedures were properly reimbursable by Medicare. The settlement woulddid not include any finding of wrong-doing or any admission of liability. As part of the settlement, the Company negotiated with the Department of Health and Human Services, Office of Inspector General (“OIG”), to obtain a release from any federal health care program permissive exclusion actions to be instituted by the OIG. During the quarter ended December 31, 2009, the Company paid $0.6 million and the remaining $0.2 million was paid prior to September 30, 2010. Both settlement agreements were executed during fiscal 2010.
     In March 2010, the DOJ issued a civil investigative demand (“CID”) pursuant to the federal False Claims Act to one of our hospitals. The CID requested information regarding Medicare claims submitted by our hospital in connection with the implantation of implantable cardioverter defibrillators (“ICDs”) during the period 2002 to the present. The Company has complied with all information requested by the DOJ for this hospital. The Company is unable to evaluate the outcome of this investigation at this time; however ICD revenue is a material component of total net revenue for this hospital and this investigation could have a material adverse effect on the Company’s financial condition and results of operations.
     In September 2010, the Company received a letter from the DOJ advising it that an investigation is being conducted to determine whether certain of the $0.8 million initially accrued withinCompany’s other accrued liabilitieshospitals have submitted claims excluded from coverage. The period of time covered by the investigation is 2003 to the present. The letter states that the DOJ’s data indicates that many of the Company’s hospitals have claims for the implantation of ICD’s which were not medically indicated and/or otherwise violated Medicare payment policy. Management understands that the DOJ has submitted similar requests to many other hospitals and hospital systems across the country as well as to the ICD manufacturers themselves. The Company is fully cooperating and has entered into a tolling agreement with the government in this investigation. To date, the DOJ has not asserted any claim against the Company’s other hospitals. Because the Company is in the early stages of this investigation, the Company is unable to estimate the outcome of this investigation. The Company’s total ICD net revenue is a material component of total net patient revenue and this investigation could have a material adverse effect on the consolidated balance sheet asCompany’s financial condition and results of September 30, 2009. Asoperations.

13


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     On January 8, 2009, the California Supreme Court ruled inProspect Medical Group, Inc., et al. v. Northridge Emergency Medical Group, et al.(2009) 45 Cal. 4th 497, that under California’s Knox-Keene statute healthcare providers may not bill patients for covered emergency out-patient services for which health plans or capitated payors are invoiced by the provider but fail to pay the provider. The California Supreme Court held that the only recourse for healthcare providers is to pursue the payors directly. TheProspectdecision does not apply to amounts that the health plan or capitated payor is not obligated to pay under the terms of June 30, 2010, $0.2 million remained accrued withinthe insured’s policy or plan. Although the decision only considered emergency providers and referred to HMOs and capitated payors, future court decisions on how the so-called “balance billing” statute is interpreted does pose a risk to healthcare providers that perform emergency or other accrued liabilities onout-patient services in the consolidated balance sheet.state of California.
     During October, 2009, a purported class action law suit was filed by an individual against the Bakersfield Heart Hospital, a consolidated subsidiary of the Company. In the complaint the plaintiff alleges that under California law, and specifically under the Knox-Keene Healthcare Service Plan Act of 1975 and under the Health and Safety Code of California, California prohibits the practice of “balance billing” for patients who are provided emergency services. A class has not been certified byOn November 24, 2010, the court in this case. Currentlygranted the Bakersfield Heart Hospital’s motion to strike plaintiff’s class allegations.
     During June 2010 and 2009, the Company is unable to predict with certainty the outcome of this case or if the plaintiff prevails whether the amount due to the plaintiff could be material.
     The Company hasentered into a one-year claims-made policy providing coverage for medical malpractice claim amounts in excess of $2.0 million of retained liability per claim. The Company additionally hasalso purchased additional insurance to reduce the retained liability per claim to $250,000 for the MedCath Partners Division.Division, for each respective fiscal year. Because of the Company’s self-insured retention levels, the Company is required to recognize an estimated expense/liability for the amount of retained liability applicable to each malpractice claim. As of June 30,December 31, 2010 and September 30, 2009,2010, the total estimated liability for the Company’s self-insured retention on medical malpractice claims, including an estimated amount for incurred but not reported claims, was $3.0$2.7 million and $4.5 million, respectively, which is included in other accrued liabilities in the consolidated balance sheets. The Company maintains this reserve based on actuarial estimates using the Company’s historical experience with claims and assumptions about future events.
     In addition to reserves for medical malpractice, the Company also maintains reserves for self-insured workman’s compensation, healthcare and dental coverage. The total estimated reserve for self-insured liabilities for workman’s compensation, employee health and dental claims was $3.4$3.0 million and $3.5$3.3 million as of June 30,December 31, 2010 and September 30, 2009,2010, respectively, which is included in other accrued liabilities in the consolidated balance sheets. The Company maintains this reserve based on historical experience with claims. The Company maintains commercial stop loss coverage for health and dental insurance program of $175,000 per plan participant.
     Commitments—The Company’s consolidated subsidiary hospitals provide guarantees to certain physician groups for funds required to operate and maintain services for the benefit of the hospital’s patients including emergency care services and anesthesiology services, among other services. These guarantees extend for the duration of the underlying service agreements. As of June 30,December 31, 2010, the maximum potential future payments that the Company could be required to make under these guarantees was approximately$31.6$25.9 million ($0.6 million related to discontinued operations) through June 2013. At June 30,December 31, 2010 the Company had total liabilities of $14.0$9.8 million ($0.6 million related to discontinued operations) for the fair value of these guarantees, of which $8.7$6.6 million is in other accrued liabilities and $0.2 million in current liabilities of discontinued operations, and $4.7$3.2 million is in other long term obligations and $0.4 million in long-term liabilities of discontinued operations.obligations. Additionally, the Company had assets of $14.2$10.2 million ($0.6 million related to discontinued operations) representing the future services to be provided by the physicians, of which $8.4$6.5 million is in prepaid expenses and other current assets and $0.2 million in current assets of discontinued operations, and $5.2$3.7 million is in other assetsassets.
8. Per Share Data
Basic— The calculation of basic earnings per share includes 150,900 and $0.4 million101,500 of restricted stock units that have vested but as of December 31, 2010 and 2009, respectively, have not been converted into common stock.
Diluted— The calculation of diluted earnings per share considers the potential dilutive effect of options to purchase 913,812, and 986,637 shares of common stock at prices ranging from $9.95 to $33.05, which were outstanding at December 31, 2010 and 2009, respectively, as well as 309,405 and 782,707 shares of restricted stock which were outstanding at December 31, 2010 and 2009, respectively. Dilutive options of 3,941 have been included in non-current assetsthe calculation of discontinued operations.diluted earnings (loss) per share at December 31, 2010. Of the outstanding stock options, 897,500 options have not been included in the calculation of diluted earnings per share at December 31, 2010 because these options were anti-dilutive. No options or restricted stock were included in the calculation of diluted earnings per share at December 31, 2009, as the consideration of such shares would be anti-dilutive due to the loss from continuing operations, net of tax.

1314


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
8. Earnings per Share Data
Basic— The calculation of basic earnings per share includes 150,900 and 95,900 of restricted stock units that have vested but as of June 30, 2010 and 2009, respectively, have not been converted into common stock. See Note 9 as it relates to restricted stock units granted to directors of the Company.
Diluted— The calculation of diluted earnings per share considers the potential dilutive effect of options to purchase 1,205,587 shares of common stock at prices ranging from $4.75 to $33.05, which were outstanding at June 30, 2009, as well as 487,335 shares of restricted stock which were outstanding at June 30, 2009. Of the outstanding stock options and restricted stock 1,692,922 and 1,637,260 have not been included in the calculation of diluted earnings per share for the three and nine months ended June 30, 2009, respectively, because the stock options and restricted stock were anti-dilutive. No options or restricted stock were included in the calculation of diluted earnings per share for the three and nine months ended June 30, 2010, as the consideration of such shares would be anti-dilutive due to the loss from continuing operations, net of taxes.
9. Stock Based Compensation
     Compensation expense from the grant of equity awards made to employees and directors isare recognized based on the estimated fair value of each award over each applicable awards vesting period. The Company estimates the fair value of equity awards on the date of grant using, either an option-pricing model for stock options or the closing market price of the Company’s stock for restricted stock and restricted stock units. Stock based compensation expense is recognized on a straight-line basis over the requisite service period for the awards that are ultimately expected to vest. Stock based compensation expense recorded during the three and nine months ended June 30,December 31, 2010 and 2009 was $0.6$1.9 million and $2.4$0.6 million, respectively. The associated tax benefits related to the compensation expense recognized for the three and nine months ended June 30,December 31, 2010 and 2009 was $0.2$0.8 million and $1.0 million, respectively. Stock based compensation expense recorded during the three and nine months ended June 30, 2009 was $0.2 million and $2.1 million, respectively. The associated tax benefits related to the compensation expense recognized for the three and nine months ended June 30, 2009 was $0.1 million and $0.8 million, respectively.
     Stock Options
     The following table summarizes the Company’s stock option activity:
                 
  For the Three Months Ended
  June 30, 2010 June 30, 2009
      Weighted-     Weighted-
  Number of Average Number of Average
  Stock Options Exercise Price Stock Options Exercise Price
Outstanding stock options, beginning of period  975,637  $22.14   1,302,587  $21.60 
                 
Exercised        (7,000)  10.95 
Cancelled  (4,000)  16.91   (90,000)  21.60 
                 
                 
Outstanding stock options, end of period  971,637  $22.17   1,205,587  $21.66 
                 

14


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
                                
 For the Nine Months Ended For the Three Months Ended
 June 30, 2010 June 30, 2009 December 31, 2010 December 31, 2009
 Weighted- Weighted- Weighted- Weighted-
 Number of Average Number of Average Number of Average Number of Average
 Stock Options Exercise Price Stock Options Exercise Price Stock Options Exercise Price Stock Options Exercise Price
Outstanding stock options, beginning of period 1,027,387 $22.25 1,776,837 $22.15  932,137 $21.89 1,027,387 $22.25 
  
Granted   82,000 17.46      
Exercised    (7,000) 10.95 
Cancelled  (55,750) 23.80  (646,250) 22.59   (18,325) 21.81  (40,750) 22.94 
          
  
Outstanding stock options, end of period 971,637 $22.17 1,205,587 $21.66  913,812 $21.89 986,637 $22.23 
          
     Restricted Stock Awards
     During the nine months ended June 30, 2010, the Company granted to employees 401,399 sharesThere were no grants of restricted stock. No shares of restricted stock were granted during the three months ended June 30,December 31, 2010. During the three and nine months ended June 30,December 31, 2009, the Company granted to employees 96,725 and 520,878369,164 shares of restricted stock, respectively.stock. Restricted stock granted to employees, excluding executives of the Company, vest annually on December 31 over a three year period. Executives of the Company (defineddefined by the Company as vice president or higher)higher, received two equal grants of restricted stock. The first grant vests annually in equal installments on December 31of each year over a three year period. The second grant vests annually onin December 31of each year, over a three year period if certain performance conditions are met. During the nine months ended June 30, 2010,All unvested restricted stock granted to employees becomes fully vested upon a change in control of the Company granted 89,600 shares of restricted stock units to directors. Duringas defined in the nine months ended June 30, 2009, the Company granted 95,900 shares of restricted stock units to directors. No restricted stock units were granted during the three months ended June 30, 2010Company’s 2006 Stock Option and 2009. Restricted stock units granted to directors are fully vested at the date of grant and are paid in shares of common stock upon each applicable director’s termination of service on the board.Award Plan. At June 30,December 31, 2010 the Company had $3.8$1.8 million of unrecognized compensation expense associated with restricted stock awards.

15


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
     The following table summarizes the Company’s restricted stock award activity:
                 
  For the Three Months Ended
  June 30, 2010 June 30, 2009
  Number of     Number of  
  Restricted Weighted- Restricted Weighted-
  Stock Awards Average Stock Awards Average
  and Units Grant Price and Units Grant Price
Outstanding restricted stock awards and units, beginning of period  1,025,700  $8.49   559,116  $9.74 
                 
Granted        96,725   9.42 
Vested  (37,800)  7.56       
Cancelled  (52,870)  8.04   (72,606)  9.40 
                 
                 
Outstanding restricted stock awards and units, end of period  935,030  $8.63   583,235  $9.73 
                 
                                
 For the Nine Months Ended For the Three Months Ended
 June 30, 2010 June 30, 2009 December 31, 2010 December 31, 2009
 Number of Number of   Number of Number of  
 Restricted Weighted- Restricted Weighted- Restricted Weighted- Restricted Weighted-
 Stock Awards Average Stock Awards Average Stock Awards Average Stock Awards Average
 and Units Grant Price and Units Grant Price and Units Grant Price and Units Grant Price
Outstanding restricted stock awards and units, beginning of period 654,327 $9.64 123,982 $19.28  884,285 $8.67 654,327 $9.64 
  
Granted 490,999 7.24 616,778 9.01    369,164 6.99 
Vested  (141,695) 8.65  (52,106) 20.50   (423,980) 9.42  (90,195) 9.30 
Cancelled  (68,601) 8.28  (105,419) 11.42     (10,026) 9.03 
          
  
Outstanding restricted stock awards and units, end of period 935,030 $8.63 583,235 $9.73  460,305 $7.99 923,270 $8.54 
          
 

1615


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
10. Reportable Segment Information
     The Company’s reportable segments consist of the Hospital Division and the MedCath Partners Division.
     Financial information concerning the Company’s operations by each of the reportable segments as of and for the periods indicated is as follows:
                 
  Three Months Ended June 30,  Nine Months Ended June 30, 
  2010  2009  2010  2009 
                 
Net revenue:                
Hospital Division $128,622  $119,838  $380,374  $366,969 
MedCath Partners Division  3,117   4,643   10,109   14,133 
Corporate and other  108   107   332   308 
             
Consolidated totals $131,847  $124,588  $390,815  $381,410 
             
                 
(Loss) income from operations:                
Hospital Division $(17,775) $2,030  $(33,854) $20,606 
MedCath Partners Division  (452)  (62)  (1,141)  (548)
Corporate and other  (4,232)  (1,823)  (9,975)  (6,868)
             
Consolidated totals $(22,459) $145  $(44,970) $13,190 
             
        
 Three Months Ended December 31, 
 2010 2009 
 
Net revenue: 
Hospital Division $86,618 $84,382 
MedCath Partners Division 2,228 3,336 
Corporate and other 54 112 
     
Consolidated totals $88,900 $87,830 
     
 
Income (loss) from operations: 
Hospital Division $4,005 $(16)
MedCath Partners Division 44  (175)
Corporate and other  (5,630)  (2,472)
     
Consolidated totals $(1,581) $(2,663)
     
        
 June 30, September 30,  December 31, September 30, 
 2010 2009  2010 2010 
Aggregate identifiable assets:  
Hospital Division $446,702 $517,849  $296,226 $414,656 
MedCath Partners Division 25,013 27,205  11,401 20,210 
Corporate and other 41,112 45,394  174,118 59,672 
          
Consolidated totals $512,827 $590,448  $481,745 $494,538 
          
     Substantially all of the Company’s net revenue in its Hospital Division and MedCath Partners Division is derived directly or indirectly from patient services. The amounts presented for Corporatecorporate and other primarily includesinclude general overhead and administrative expenses and financing activities as components of (loss) income from operations and certain cash and cash equivalents, prepaid expenses, other assets and operations of the business not subject to separate segment reporting within identifiable assets.
     The Hospital Division assets include $71.3 million and $72.4 million of assets related to discontinued operations as of June 30, 2010 and September 30, 2009, respectively. The MedCath Partners Division assets included $1.6 million and $19.9 million of assets related to discontinued operations as of June 30, 2010 and September 30, 2009, respectively.
11. Intangible AssetsBusiness Ownership Changes
     Change in Ownership Due to Cancellation of Stock Subscription Receivable —Upon the formation of Hualapai Mountain Medical Center the minority owners entered into stock subscription agreements whereby they paid for their ownership in two installments. At the date of formation, the amount due from the minority owners was recorded as a stock subscription receivable. During the fourth quarter of fiscal 2010, several minority owners did not submit the final installment. As of June 30, 2010a result, and September 30, 2009,per the partnership operating agreement, the proportionate ownership was transferred to the Company and the stock subscription receivable was reduced accordingly. As a result, the Company’s intangible assets, which are includedownership in other assets on the consolidated balance sheets, are detailed in the following table:
                 
  June 30, 2010 September 30, 2009
  Gross Carrying Accumulated Gross Carrying Accumulated
  Amount Amortization Amount Amortization
Intangible Assets $555  $(256) $555  $(213)
     The estimated aggregate amortization expense for each of the next five year periods ending June 30 are $57 for fiscal 2010, $45 for fiscal 2011, and $32 for fiscal 2012, 2013, and 2014.

17


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
HMMC increased from 79.00% to 82.49%.
12. Comprehensive Income
                 
  Three Months Ended June 30,  Nine Months Ended June 30, 
  2010  2009  2010  2009 
Net (loss) income $(10,461) $2,769  $(20,964) $18,184 
Changes in fair value of interest rate swap, net of tax benefit  (67)  126   (35)  (147)
             
Comprehensive (loss) income  (10,528)  2,895   (20,999)  18,037 
Less: Net income attributable to noncontrolling interest  (2,355)  (2,273)  (5,718)  (9,860)
             
Comprehensive (loss) income attributable to MedCath Corporation common stockholders $(12,883) $622  $(26,717) $8,177 
             
13. Property and Equipment
         
  June 30,  September 30, 
  2010  2009 
         
Land $30,558  $32,629 
Buildings  234,194   263,796 
Equipment  225,385   217,362 
Construction in progress  1,077   17,434 
       
Total, at cost  491,214   531,221 
Less accumulated depreciation  (201,353)  (189,827)
       
Property and equipment, net $289,861  $341,394 
       
     During the three and nine months ended June 30, 2010 the Company recorded $22.8 million and $42.8 million of impairment charges to the consolidated statement of operations, respectively. See Note 1 for further discussion related to these impairment charges.
14. Other Assets
     The Company’s Corporate and other division entered into a note receivable agreement with a third party during 2008. During the second quarter ended March 31, 2010, the Company deemed the note receivable to be uncollectable due to the third party’s inability to repay the note and the insufficiency of the value of the collateral securing the note. As a result a loss of $1.5 million was recorded on the consolidated statement of operations during the nine months ended June 30, 2010.
         
  December 31,  September 30, 
  2010  2010 
         
Land $17,635  $17,635 
Buildings  149,901   149,897 
Equipment  155,972   163,746 
Construction in progress  29   25 
       
Total, at cost  323,537   331,303 
Less accumulated depreciation  (146,652)  (149,081)
       
Property and equipment, net $176,885  $182,222 
       

1816


MEDCATH CORPORATION
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(All tables in thousands, except percentages and per share data)
15.13. Fair Value Measurements
     As described in Note 2Recent Accounting Pronouncementsthe Company adopted the accounting standard issued by the FASB that defines fair value, establishes a framework for measuring fair value and enhances disclosures about fair value measures required under other accounting pronouncements. The FASB delayed the effective date of this new standard for all nonfinancialCompany’s non-financial assets and liabilities whose fair values are measured on a nonrecurring basis, typically relate to long-lived assets. The Company is nownot permitted or required to provide additional disclosures about fair value measurements for each major category of assets and liabilitiesbe measured at fair value on a non-recurring basis.recurring basis typically relate to long-lived assets held and used and long-lived assets held for sale (including investments in affiliates). Fair values are determined by as follows:
Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non-financial assets and liabilities.
Level 2 inputs utilize data points that are observable, such as independent third party market offers.
Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of discounted cash flows or third party appraisals.
     The Company considers the carrying amounts of significant classes of financial instruments on the consolidated balance sheets to be reasonable estimates of fair value due either to their length to maturity or liabilities, which generally are not applicable to non-financial assetsthe existence of variable interest rates underlying such financial instruments that approximate prevailing market rates at December 31, 2010 and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as independent third party market offers. Fair values determined bySeptember 30, 2010. Based on Level 3 inputs, are unobservable data points for the asset or liability and include situations where there is little, if any, market activity forfair value of long-term debt, including the asset or liability, such as internal estimates of discounted future cash flows or third party appraisals.
     As of Marchcurrent portion, at December 31, 2010 approximates the fair values of certain longed lived assets within the Hospital Division were $78.9 million, $32.0 million was derived from Level 2 inputs and $46.9 million was derived fromcarrying value. Based on Level 3 inputs, resulting in an impairmentthe fair value of $19.9 million forlong-term debt, including the three and six month period ended March 31, 2010.
     As of Junecurrent portion, at September 30, 2010 the fairwas $108.1 million ($41.5 million related to discontinued operations) as compared to carrying values of certain long lived assets within the Hospital Division and Corporate and other were $54.3$101.2 million all($34.6 million related to discontinued operations). The fair value of which was derived from Level 2 inputs, resulting in an impairment of $22.8 million for the three month period ended June 30, 2010 and $42.8 million for the nine months ended June 30, 2010. See Notes 1 and 13 for further disclosure regarding these impairments.
16. Income Taxes
     As of June 30, 2010 the Company had a net deferred tax asset of $12.9 million, $12.3 million were current deferred tax assets and $0.6 million were long term deferred tax assets. As of September 30, 2009 the Company had a net deferred tax liability of $1.7 million, $12.2 million were current deferred tax assets and $13.9 million were long term deferred tax liabilities. The change in the Company’s net deferred tax positionvariable rate debt was primarilydetermined to approximate its carrying value due to the recordingunderlying variable interest rates.
     The Company’s cash equivalents are measured utilizing Level 1 or Level 2 inputs.
14. Subsequent Events
     On January 1, 2011, MedCath Partners sold its investment in one of $8.8its investments accounted for under the equity method for $0.6 million.
     On January 5, 2011, the Company made a principal repayment of $20.6 million and $16.4using the proceeds from asset dispositions, thereby reducing the outstanding balance under the Amended Credit Facility to $38.3 million in deferred taxat that date.
     In January 2011, the Company obtained from its noncontrolling members of one of its hospitals, the right to sell all or substantially all of the assets in connectionof that hospital. Concurrent with the granting of such right and as a condition thereto, an approval, consent and proxy were obtained from the Company’s impairmentsnoncontrolling members in the hospital. The approval, consent and proxy allows the Company to sell all or substantially all of propertythe assets of that hospital and equipment during the three and nine month periods ended June 30, 2010, respectively.Company will pay to the noncontrolling members the net amount of their unreturned capital contributions ($3.0 million at December 31, 2010) adjusted upward for any proportionate share of additional proceeds upon a disposition transaction.

1917


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
     The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the interim unaudited consolidated financial statements and related notes included elsewhere in this report, as well as the audited consolidated financial statements and related notes thereto and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in our Annual Report onForm 10-K for the fiscal year ended September 30, 2009.2010.
Overview
     General. We are a healthcare provider focused primarily on providing high acuity services, predominantlyincluding the diagnosis and treatment of cardiovascular disease. We own and operate hospitals in partnership with physicians whom we believe have established reputations for clinical excellence. We have ownershipAs noted below, during the first quarter of fiscal 2011, we sold three of our majority owned hospitals and our equity interest in one of our minority owned hospitals. As a result, at December 31, 2010, we currently own interests in and operate tensix hospitals, with a total of 825 licensed beds, 58 of which are related to HHA, whose assets, liabilities, and operations are included within discontinued operations. Our nine hospitals that currently comprise our continuing operations have 767533 licensed beds, of which 678489 are staffed and available, and that are located in sevenfive states: Arizona, Arkansas, California, Louisiana, New Mexico South Dakota, and Texas.During May 2009, we completedTexas. Each of our 79majority-owned hospitals is a freestanding, licensed bed expansion at Louisiana Medical Center and Heart Hospital (“LMCHH”) and built space for an additional 40 beds at that hospital. During October 2009, we opened a newgeneral acute care hospital Hualapai Mountain Medical Center (“HMMC”), in Kingman, Arizona. This hospital is designed to accommodatethat provides a totalwide range of 106 licensed beds,health services with an initial openinga majority focus on cardiovascular care. Each of 70 of its licensed beds.our hospitals has a 24-hour emergency room staffed by emergency department physicians.
     In addition to our hospitals, we currently own and/or manage 12seven cardiac diagnostic and therapeutic facilities. NineSix of these facilities are located at hospitals operated by other parties. These facilities offer invasive diagnostic and, in some cases, therapeutic procedures. The remaining three facilities arefacility is not located at hospitalsa hospital and offers only diagnostic procedures. The Company also operates two mobile cardiac catheterization laboratories which operate on set routes and offer only diagnostic procedures. We refer to our diagnostics division as “MedCath Partners.”
     InPursuant to a favorable regulatory settlement (“Settlement Agreement”) that MedCath entered into on August 14, 1995 with the State of North Carolina Department of Human Resources (now known as the Division of Health Service Regulation (“DHSR”)), MedCath obtained authority to operate nine cardiac catheterization laboratories within the state of North Carolina. The rights under the Settlement Agreement were subsequently assigned to MedCath Partners in connection with a reorganization by MedCath. The Settlement Agreement allows MedCath Partners to operate these catheterization labs anywhere in North Carolina without a need for further state review, with some exceptions. No certificate of need (“CON”) is required for MedCath Partners to operate any one of these nine diagnostic or interventional laboratories in the state. MedCath Partners is required to comply with certain notice requirements for replacement of any equipment in these laboratories and has historically notified the DHSR when MedCath Partners is changing the location of any laboratories located within the State. However, the DHSR takes the position that MedCath Partners must own and provide the services of the equipment which comprises each laboratory — the CON exemption applies only when MedCath Partners is operating one of these specific nine laboratories.
     On March 1, 2010, the Company’swe announced that our Board of Directors began thehad formed a Strategic Alternatives ReviewOptions Committee to consider the sale either of either the Company or the sale of itsour individual hospitals and other assets. The Strategic Alternatives ReviewWe retained Navigant Capital Advisors as our financial advisor to assist in this process. Since announcing the exploration of strategic alternatives on March 1, 2010, we have completed several transactions, including:
The disposition of Arizona Heart Hospital (Phoenix, AZ) in which we sold the majority of the hospital’s assets to Vanguard Health Systems for $32.0 million, plus retained working capital. The transaction was completed effective October 1, 2010. We anticipate that we will receive final net proceeds of approximately $31.5 million from the transaction after payment of retained known liabilities, payment of taxes related to the transaction and collection of the hospital’s accounts receivable. The $31.5 million in estimated net proceeds is prior to any reserves, if any, required in management’s judgment to address any potential contingent liabilities.
The disposition of our wholly owned subsidiary that held 33.3% ownership of Avera Heart Hospital of South Dakota (Sioux Falls, SD) to Avera McKennan for $20.0 million, plus a percentage of the hospital’s available cash. The transaction was completed October 1, 2010. We estimate that we will receive final net proceeds from the transaction of approximately $16.0 million, after payment of estimated taxes related to the transaction and prior to reserves, if any, required in management’s judgment to address any potential contingent liabilities.
The disposition of Heart Hospital of Austin (Texas) in which we and our physician owners sold substantially all of the hospital’s assets to St. David’s Healthcare Partnership L.P. for approximately $83.8 million, plus retained working capital. The transaction was completed effective November 1, 2010. We anticipate that we will receive final net proceeds of approximately $24.1 million from the transaction after repayment of third party debt and a related prepayment fee, payment of all known retained liabilities of the partnership, payment of taxes related to the transaction, collection of the partnerships accounts receivable, and distributions to the hospital’s minority partners. The $24.1 million in estimated net proceeds is prior to reserves, if any, required in management’s judgment to address any potential contingent liabilities.

18


The disposition of our approximate 27.0% ownership interest in Southwest Arizona Heart and Vascular, LLC (Yuma, AZ) to the joint venture’s physician partners for $7.0 million. The transaction was completed effective November 1, 2010. We estimate that final net proceeds from the transaction will total approximately $6.9 million, after closing costs and income tax benefit related to a tax loss on the transaction, but prior to reserves, if any, required in management’s judgment to address any potential contingent liabilities.
The disposition of TexSan Heart Hospital (San Antonio, Texas) in which we and our physician owners sold substantially all of the hospital’s assets to Methodist Healthcare System of San Antonio for $76.25 million, plus retained working capital. The transaction was completed on December 31, 2010. We estimate that final net proceeds from the transaction will total approximately $60.8 million, after closing costs and income taxes on the transaction, but prior to reserves, if any, required in management’s judgment to address any potential contingent liabilities.
     We cannot assure our investors that our continuing efforts to enhance stockholder value will be successful, or whether future transactions will involve a sale of the Company, a sale of our individual hospitals or other assets, or a combination of these alternatives. We continue to consider all practicable alternatives to maximize stockholder value. Although the strategic options process is continuing. The Company cannot provide any assurance regardingon-going and expected to continue throughout fiscal 2011 and potentially beyond, we have begun to consider a number of scenarios for distributing available cash to our stockholders, such as special cash dividends and/or distributions to stockholders following future sales of individual hospitals or other assets or in the resultcontext of this process. As a result, the Company’s Strategic Alternatives Review process may collect information relative to the fair market valuedissolution, and following repayment of all bank debt and termination of our assetscredit facility. If our common equity is sold in a merger or other similar transaction, then stockholders would receive consideration in exchange for their shares in accordance with the terms of that transaction.
     Many unknown variables, including those related to seeking any approvals which could resultmay be required, will affect the amount, timing and mechanics of any potential distributions to stockholders. Until further progress is made in additional impairments. However, generally accepted accounting principles do not allow usthe strategic options process, we are unable to recognize a gain ifdetermine the fair valueapproach that best meets the interests of our assets exceeds their carrying value until the disposition of those assets occurs.
Same Facility Hospitals.Our policy isstockholders. Final amounts available to include, on a same facility basis, only those facilities that were openstockholders will be diminished by asset and operational during the full currentcorporate wind-down related operating and prior fiscal year comparable periods. For example, on a same facility basis for our consolidated Hospital Division for the threeother expenses, continued debt service obligations, tax treatment, inability to collect all amounts owed and nine months ended June 30, 2010, we exclude the results of operations of Hualapai Mountain Medical Center, which opened in October 2009.any required reserves to address liabilities, including retained and contingent liabilities and/or other unforeseen events.
     Revenue Sources by Division.The largest percentage of our net revenue is attributable to our Hospital Division.hospital division. The following table sets forth the percentage contribution of each of our consolidating divisions to consolidated net revenue in the periods indicated below.
                        
 Three Months Ended June 30, Nine Months Ended June 30, Three Months Ended December 31,
Division 2010 2009 2010 2009 2010 2009
Hospital  97.5%  96.2%  97.3%  96.2%  97.4%  96.1%
MedCath Partners  2.4%  3.7%  2.6%  3.7%  2.5%  3.8%
Corporate and other  0.1%  0.1%  0.1%  0.1%  0.1%  0.1%
              
Net Revenue  100.0%  100.0%  100.0%  100.0%  100.0%  100.0%
              

20


     Revenue Sources by Payor.We receive payments for our services rendered to patients from the Medicare and Medicaid programs, commercial insurers, health maintenance organizations and our patients directly. Generally, ourOur net revenue is determinedimpacted by a number of factors, including the payor mix, the number and nature of procedures performed and the rate of payment for the procedures. Since cardiovascular disease disproportionately affects those age 55 and older, the proportion of net revenue we derive from the Medicare program is higher than that of most general acute care hospitals. The following table sets forth the percentage of consolidated net revenue we earned by category of admitting payor in the periods indicated.
                        
 Three Months Ended June 30, Nine Months Ended June 30, Three Months Ended December 31,
Payor 2010 2009 2010 2009 2010 2009
Medicare  49.9%  50.1%  52.9%  52.5%  50.8%  53.9%
Medicaid  5.0%  2.8%  4.7%  3.5%  4.3%  3.9%
Commercial and other, including self-pay  45.1%  47.1%  42.4%  44.0%  44.9%  42.2%
              
Total consolidated net revenue  100.0%  100.0%  100.0%  100.0%  100.0%  100.0%
              
     A significant portion of our net revenue is derived from federal and state governmental healthcare programs, including Medicare and Medicaid, and we expect the net revenue that we receive from the Medicare program as a percentage of total consolidated net revenue towill remain significant in future periods. Our payor mix may fluctuate in future periods due to changes in reimbursement, market and industry trends with self-pay patients, and other similar factors.

19


     The Medicare and Medicaid programs are subject to statutory and regulatory changes, (such as the Health Reform Laws), retroactive and prospective rate adjustments, administrative rulings, court decisions, audits, investigations, executive orders and freezes and funding reductions, all of which may significantly affect our business. In addition, reimbursement is generally subject to adjustment and possible recoupment following audit by all third party payors, including commercial payors and the fiscal intermediariescontractors who administer the Medicare program i.e.,for the CMS.Center for Medicare and Medicaid Services (“CMS’) as well as the Office of Inspector General. Final determination of amounts due providers under the Medicare program often takes several years because of such audits, as well as resulting provider appeals and the application of technical reimbursement provisions. We believe that adequate provision has been made for any adjustments that might result from these programs; however, due to the complexity of laws and regulations governing the Medicare and Medicaid programs, the manner in which they are interpreted and the other complexities involved in estimating our net revenue, there is a possibility that recorded estimates will change by a material amount in the future.

21


Results of Operations
Three Months Ended June 30,December 31, 2010 Compared to Three Months Ended June 30,December 31, 2009
     Statement of Operations Data.The following table presents our results of operations in dollars and as a percentage of net revenue for the periods indicated:
                         
  Three Months Ended June 30, 
  (in thousands except percentages) 
          Increase/(Decrease)  % of Net Revenue 
  2010  2009  $  %  2010  2009 
Net revenue $131,847  $124,588  $7,259   5.8%  100.0%  100.0%
Operating expenses:                        
Personnel expense  44,546   43,854   692   1.6%  33.8%  35.2%
Medical supplies expense  35,706   36,472   (766)  (2.1)%  27.1%  29.3%
Bad debt expense  13,642   10,406   3,236   31.1%  10.3%  8.3%
Other operating expenses  29,935   26,537   3,398   12.8%  22.7%  21.3%
Pre-opening expenses     754   (754)  (100.0)%     0.6%
Depreciation  7,636   6,466   1,170   18.1%  5.8%  5.2%
Amortization  8   8             
Impairment of property and equipment  22,813      22,813   100.0%  17.3%   
Loss (gain) on disposal of property, equipment and other assets  20   (54)  74   137.0%      
                   
(Loss) income from operations  (22,459)  145   (22,604)  N/M   (17.0)%  0.1%
Other income (expenses):                        
Interest expense  (1,131)  (396)  (735)  185.6%  (0.8)%  (0.3)%
Interest and other income  62   48   14   29.2%      
Equity in net earnings of unconsolidated affiliates  2,262   2,265   (3)  (0.1)%  1.7%  1.8%
                   
(Loss) income from continuing operations before income taxes  (21,266)  2,062   (23,328)  N/M   (16.1)%  1.6%
Income tax (benefit) expense  (8,642)  171   (8,813)  N/M   (6.6)%  0.1%
                   
(Loss) income from continuing operations  (12,624)  1,891   (14,515)  (767.6)%  (9.5)%  1.5%
Income from discontinued operations, net of taxes  2,163   878   1,285   146.4%  1.6%  0.7%
                   
Net (loss) income  (10,461)  2,769   (13,230)  (477.8)%  (7.9)%  2.2%
Less: Net income attributable to noncontrolling interest  (2,355)  (2,273)  (82)  3.6%  (1.8)%  (1.8)%
                   
Net (loss) income attributable to MedCath Corporation $(12,816) $496  $(13,312)  N/M   (9.7)%  0.4%
                   
                         
Amounts attributable to MedCath Corporation common stockholders:                        
(Loss) income from continuing operations, net of taxes $(14,155) $23  $(14,178)  N/M   (10.7)%   
Income from discontinued operations, net of taxes  1,339   473   866   183.1%  1.0%  0.4%
                   
Net (loss) income $(12,816) $496  $(13,312)  N/M   (9.7)%  0.4%
                   
                     
      Three Months Ended December 31,     
  (in thousands except percentages) 
          Increase/    
          (Decrease)  % of Net Revenue 
  2010  2009  %  2010  2009 
Net revenue $88,900  $87,830   1.2%  100.0%  100.0%
Operating expenses:                    
Personnel expense  32,454   31,636   2.6%  36.5%  36.0%
Medical supplies expense  19,222   22,107   (13.1)%  21.6%  25.2%
Bad debt expense  9,709   7,506   29.3%  10.9%  8.5%
Other operating expenses  24,116   22,344   7.9%  27.1%  25.4%
Pre-opening expenses     866   (100.0)%     1.0%
Depreciation  4,887   5,938   (17.7)%  5.5%  6.8%
Loss on disposal of property, equipment and other assets  93   96   (3.1)%  0.1%  0.2%
                
Loss from operations  (1,581)  (2,663)  (40.6)%  (1.8)%  (3.0)%
Other income (expenses):                    
Interest expense  (1,082)  (945)  (14.5)%  (1.2)%  (1.1)%
Interest and other income, net  489   70   (598.6)%  0.6%  0.1%
Gain on sale of unconsolidated affiliates  15,391      N/M   17.3%   
Equity in net earnings of unconsolidated affiliates  602   1,516   (60.3)%  0.7%  1.6%
                
Income (loss) from continuing operations before income taxes  13,819   (2,022)  (783.4)%  15.6%  (2.3)%
Income tax expense (benefit)  4,482   (1,337)  (435.2)%  5.0%  (1.5)%
                
Income (loss) from continuing operations  9,337   (685)  (1463.1)%  10.5%  (0.8)%
Income (loss) from discontinued operations, net of taxes  39,128   (1,130)  (3562.7)%  44.0%  (1.3)%
                
Net income (loss)  48,465   (1,815)  (2770.2)%  54.5%  (2.1)%
Less: Net income attributable to noncontrolling interest  (11,426)  (841)  1258.6%  (12.9)%  (1.0)%
                
Net income (loss) attributable to MedCath Corporation $37,039  $(2,656)  (1494.5)%  41.7%  (3.0)%
                
                     
Amounts attributable to MedCath Corporation common stockholders:                    
Income (loss) from continuing operations, net of taxes $7,162  $(1,902)  (476.6)%  8.1%  (2.2)%
Income (loss) from discontinued operations, net of taxes  29,877   (754)  (4062.5)%  33.6%  (0.9)%
                
Net income (loss) $37,039  $(2,656)  (1494.5)%  41.7%  (3.0)%
                

20


     The following table presents selected operating data on a consolidated basis for the periods indicated:
             
  Three Months Ended December 31,
  2010 2009 % Change
             
Selected Operating Data (a):
            
Number of hospitals  5   5     
Licensed beds (b)  421   421     
Staffed and available beds (c)  380   380     
Admissions (d)  4,438   4,482   (1.0)%
Adjusted admissions (e)  6,841   6,485   5.5%
Patient days (f)  16,254   16,672   (2.5)%
Adjusted patient days (g)  25,143   24,324   3.4%
Average length of stay (days) (h)  3.66   3.72   (1.4)%
Occupancy (i)  46.5%  47.7%    
Inpatient catheterization procedures (j)  1,792   1,964   (8.8)%
Inpatient surgical procedures (k)  1,032   1,085   (4.9)%
Hospital net revenue (in thousands except percentages) $86,618  $84,382   2.6%
 
N/MNot meaningful
     HMMC, which is located in Kingman, AZ, opened in October 2009. For comparison purposes, the selected operating data below are presented on an actual consolidated basis and on a same facility basis for the periods indicated. Same facility basis excludes HMMC from operations for the three and nine months ended June 30, 2010.
                     
  Three Months Ended June 30,
              2010 Same  
  2010 2009 % Change Facility % Change
                     
Selected Operating Data (a):
                    
Number of hospitals  7   6       6     
Licensed beds (b)  600   530       530     
Staffed and available beds (c)  514   484       444     
Admissions (d)  6,526   5,653   15.4%  6,042   6.9%
Adjusted admissions (e)  9,741   8,594   13.3%  8,837   2.8%
Patient days (f)  24,276   22,795   6.5%  22,582   (0.9)%
Adjusted patient days (g)  36,474   34,803   4.8%  33,284   (4.4)%
Average length of stay (days) (h)  3.72   4.03   (7.7)%  3.74   (7.2)%
Occupancy (i)  51.9%  51.8%      55.9%    
Inpatient catheterization procedures (j)  2,971   2,735   8.6%  2,903   6.1%
Inpatient surgical procedures (k)  1,865   1,809   3.1%  1,769   (2.2)%
Hospital net revenue (in thousands except percentages) $127,613  $118,104   8.1% $120,148   1.7%

22


(a) Selected operating data includes consolidated hospitals in operation as of the end of the period reported in continuing operations but does not include hospitals which are accounted for using the equity method or as discontinued operations in our consolidated financial statements.
 
(b) Licensed beds represent the number of beds for which the appropriate state agency licenses a facility regardless of whether the beds are actually available for patient use.
 
(c) Staffed and available beds represent the number of beds that are readily available for patient use at the end of the period.
 
(d) Admissions represent the number of patients admitted for inpatient treatment.
 
(e) Adjusted admissions areis a general measure of combined inpatient and outpatient volume. We compute adjusted admissions by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by admissions.
 
(f) Patient days represent the total number of days of care provided to inpatients.
 
(g) Adjusted patient days areis a general measure of combined inpatient and outpatient volume. We compute adjusted patient days by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by patient days.
 
(h) Average length of stay (days) represents the average number of days inpatients stay in our hospitals.
 
(i) We compute occupancy by dividing patient days by the number of days in the period and then dividing the quotient by the number of staffed and available beds.
 
(j) Inpatient catheterization procedures represent the number of inpatients with a procedure performed in one of the hospitals’ catheterization labs during the period.
 
(k) Inpatient surgical procedures represent the number of surgical procedures performed on inpatients during the period.
Net Revenue.Our consolidated net revenue increased 5.8%1.2% or $7.2$1.1 million to $131.8$88.9 million for the thirdfirst quarter of fiscal 20102011 from $124.6$87.8 million for the thirdfirst quarter of fiscal 2009.2010. Hospital Division net revenue increased 7.3%2.6%, or $8.8$2.2 million, for the thirdfirst quarter of fiscal 20102011 compared to the same period of fiscal 2009. Beginning2010. There was a $1.1 million decrease in net revenue in our MedCath Partners Division.
     Inpatient net revenue was 69% of the Hospital Division’s net patient revenue for the first quarter of fiscal 2011 compared to 71% for the first quarter of fiscal 2010. Our total inpatient net revenue and cases decreased 3.4% and 2.0%, respectively during the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010, our MedCath Partners Division renegotiated certain management contracts, joint ventures, and management agreements. As a result, our MedCath Partners Divisionwhereas outpatient net revenue declined $1.5 millionand cases increased 9.3% and 31.5%, respectively during the thirdsame period.
     The decrease in inpatient net revenue is due to a 6.5% decline in our core cardiovascular cases offset by an 8.0% increase in our non-cardiovascular cases. Hualapai Mountain Medical Center, (“HMMC”), our newest hospital which began operations during the first quarter of fiscal 2010, is a general acute care facility so it contributed to the increase in our non-cardiovascular procedures for the first quarter of fiscal 2011 compared to the same period of fiscal 2009. Netthe prior year. HMMC’s inpatient cases increased 106% due to the ramp up of the facility. HMMC also contributed to the increase in outpatient cases and net revenue, on a same facility basis was as follows:
                         
  Three Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Net revenue $124,382  $124,588  $(206)  (0.2)%  100.0%  100.0%
particularly related to emergency department cases.

2321


     SameExcluding HMMC from both the first quarter of fiscal 2011 and 2010 (“same facility” basis), inpatient net revenue decreased $2.4 million, or 4.1%, and outpatient net revenue increased $1.1 million, or 5.0%, for the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010. Our same facility inpatient net revenue was 69.5% of the Hospital Division’s total same facility net patient revenue for the third quarter of fiscal 2010 compared to 65.9% for the third quarter of fiscal 2009. Inpatient cases for the third quarter of fiscal 2010 increased 6.9% compared to the third quarter of the prior year, however our total inpatient net revenue remained relatively flat as a result of a decline in procedures with higher net revenue per case such as open heart and AICD procedures. Inpatient open heart and AICD net revenues were down 12.9% and 18.2%, respectively, during the third quarter of fiscal 2010 as compared to the comparable period of fiscal 2009. We believe the decline is indicative that less invasive cardiac procedures, such as stents, and pharmaceutical treatments have been increasingly successful in treating patients suffering from cardiovascular disease. These decreases were offset by a 10.3% increase in inpatient bare metal and drug eluting stent procedures and a 48.1% increase in non-core procedure related net revenue. Inpatient stent revenues have increased as a result of the utilization of an independent third party to assist with the determination of patient clinical setting. The increase in non-cardiac related net revenuedecrease is due to the Hospital Division’s focus on diversifyingmix of procedures performed. We performed fewer procedures with higher reimbursement during the business from a dependence on cardiac cases and increasing cases in emergency department visits due to several of our hospital expansions.
     Outpatient cases, excluding emergency department cases, and net revenue decreased 2.3% and 3.2%, respectively for the thirdfirst quarter of fiscal 2010 compared to the third quarter of fiscal 2009. As noted above, the decrease in outpatient cases and net revenue was primarily due to the use of an independent third party to assist with the proper classification of patients as inpatient or outpatient. Emergency department visits and net revenue increased 5.9% and 8.1%, respectively for the third quarter of fiscal 20102011 compared to the same period of fiscal 2009the prior year. Our same facility outpatient revenue increase is due to a 7.1% increase in same facility outpatient cases, particularly emergency department cases, due to the mixexpansion at several of theour facilities and more procedures performed.being performed in an outpatient setting.
     Same facility netNet revenue for the thirdfirst quarter of fiscal 20102011 included charity care deductions of $1.9$2.1 million compared to charity care deductions of $0.6$1.9 million for the thirdfirst quarter of fiscal 2009.2010. The increase is the result of more uninsured patients applying and qualifying for charity care.
     Personnel expense.Our consolidated personnelPersonnel expense increased 1.6%2.6%, or $0.9 million, to $44.5$32.5 million for the thirdfirst quarter of fiscal 20102011 from $43.9$31.6 million for the thirdfirst quarter of fiscal 2009. Personnel expense on a same facility basis was as follows:
                         
  Three Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Personnel expense $41,208  $43,854  $(2,646)  (6.0)%  33.1%  35.2%
2010.
     The $2.6 million reductionincrease in same facility personnel expense was primarily due to an overall reduction in the majority of all personnel related expenses to better align our expenses with the level of care required for our patients. We also incurred a $0.6$1.3 million reduction in other salaries and wages expense attributable to our MedCath Partners Division due to a decrease in the staff related to fewer ventures. These decreases were partially offset by an increase of $0.4 million in stock based compensation. Certain employees and directors were grantedcompensation expense. As part of the strategic options process, the compensation committee of our Board of Directors waived the performance vesting criteria for certain executive management’s restricted stock shares during the first quarter of fiscal 2010 and 2009, thus incrementally increasing our quarterly expense. We recognize employee restricted2011 to ensure the deductibility of the compensation expense for federal corporate income tax purposes. The waiver caused all future stock based compensation expense related to the shares that would have vested over time as performance criteria were met to be recognized during the periodsfirst quarter of fiscal 2011. The shares subject to the waiver of vesting criteria contain transfer restrictions that will remain in which they are expectedplace until a change in control of the Company. In addition, management updated the estimate on the restricted share forfeiture rate since it is anticipated that the rate of employee turnover will decline as we continue to vest.progress with our strategic options process. We experienced a $0.5 million increase in expense related to hospital employee healthcare claims. This expense is directly attributed to the number of claims reported during the period. These increases were offset by a $0.9 million decline in salaries and wages and related benefits as we continue to monitor costs to better align these costs with net revenues and as the result of a reduction in management positions within hospital division as we sell our hospital assets.
     Medical supplies expense.Our consolidatedMedical supplies expense decreased 13.1%, or $2.9 million, to $19.2 million for the first quarter of fiscal 2011 from $22.1 million for the first quarter of fiscal 2010. This decline is due to $2.9 million in sales tax refunds at two of our hospitals. Absent the refunds, medical supplies expense decreased 2.1% to $35.7was flat year over year. Medical supplies expense increased $0.7 million forat HMMC which began operations in the thirdsecond month of the first quarter of fiscal 2010 from $36.5 millionresulting in higher supply expense for the thirdfirst quarter of fiscal 2009. Medical supplies2011. This increase was offset by a decline in ICD expense onas the result of a same facility basis was as follows:
                         
  Three Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Medical supplies expense $34,363  $36,472  $(2,109)  (5.8)%  27.6%  29.3%
     The majority of the $2.1 million decrease7.6% decline in medical suppliesICD procedures for the thirdfirst quarter of fiscal 20102011 compared to the same period of the prior year is attributable to the decline in open heart and AICD cases. Cardiac related cases such as open heart and AICD procedures have higher supply related costs compared to the supply costs of our non-cardiac related cases. In addition, we have negotiated a decline in the unit cost of our drug-eluting stents and our utilization of stents per case has declined.year.

24


     Bad debt expense.Our consolidated badBad debt expense increased 31.1%29.3%, or $2.2 million, to $13.6$9.7 million for the thirdfirst quarter of fiscal 20102011 from $10.4$7.5 million for the thirdfirst quarter of fiscal 2009.2010. As a percentage of net revenue, bad debt expense increased to 10.3%10.9% for the thirdfirst quarter of fiscal 20102011 as compared to 8.3%8.5% for the comparable period of fiscal 2009. Bad2010. This increase is due to a 68.8%, or $3.2 million, increase in self-pay net revenue for the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010. We reserve for the estimated bad debt expense on a same facility basisself-pay net revenue at the time of recognition based on our historical collection experience related to self-pay patients. This increase was as follows:
                         
  Three Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Bad debt expense $12,506  $10,406  $2,100   20.2%  10.1%  8.3%
     Our total same facility uncompensated care including charity care andoffset by lower bad debt expense was 11.8% of total same facilityin certain markets due to lower net patient hospital revenue for the thirdfirst quarter of fiscal 20102011 compared to 9.2% of total same facility net patient revenue for the thirdfirst quarter of fiscal 2009. The total number of patients that applied and qualified for charity care increased during the third quarter of fiscal 2010 compared to the third quarter of fiscal 2009. We reported $1.3 million more charity care deductions to net revenue during the third quarter of fiscal 2010 when compared to the third quarter of fiscal 2009. Bad debt expense alone (not including charity care) increased $2.1 million for the third quarter of fiscal 2010 compared to the same period of fiscal 2009. The increase in bad debt expense is directly attributable to an increase in the patient account receivable balance after insurance plan payments. Our self-pay accounts receivable after insurance balance prior to bad debt reductions has increased approximately 15.3% for the third quarter of fiscal 2010 compared to the balance for the third quarter of fiscal 2009.2010.
     Other operating expenses.Our consolidated otherOther operating expenses increased 12.8%7.9%, or $1.8 million, to $29.9$24.1 million for the thirdfirst quarter of fiscal 20102011 from $26.5$22.3 million for the thirdfirst quarter of fiscal 2009. Other operating expense on a same facility basis was as follows:
                         
  Three Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Other operating expense $27,673  $26,537  $1,136   4.3%  22.2%  21.3%
     Our total same facility other operating expense increased $1.1 million for the third quarter of fiscal 2010 compared to fiscal 2009.2010. The material and notable increases (decreases) in operating expenses were as reflected below (in millions):
     
Salaries, wages and bonus expense of corporate division $0.7 
Primary care practice expenses $0.6 
Property tax $0.3 
Purchased services $0.4 
Repairs and maintenance $0.3 
Professional fees $(0.4)
Fees and penalties $(0.8)
     
Professional fees $1.2 
Purchased services — nonclinical $0.7 
Corporate division medical benefits $0.4 
Repairs and maintenance $0.3 
Temporary labor $0.3 
Insurance expense $0.2 
Bonus expense $0.2 
Physician practice expenses $(0.3)
Recruiting, relocation and travel expense $(0.4)
Salaries and wages $(0.6)
     Corporate salariesOur professional fees have increased $1.2 million as the direct result of our strategic options process, which included the sale of several of our assets and wages have declined $1.0 million duethe exploration of alternatives for the sale of our remaining assets or our equity. We will continue to natural attrition related toincur professional fees during fiscal 2011 as our Strategic Alternatives Review and a reduction in hiring of new employees as we explore these alternatives. In addition, we incurred $0.4strategic options process continues.
     Our purchased services — nonclinical expense includes $1.3 million in severancethird party consulting fees to obtain sales tax refunds on medical supplies at certain of our hospitals. As noted above under medical supplies expense, we filed sales tax refund claims of $2.9 million during the thirdfirst quarter of fiscal 2009 compared2011. The increase related to no severancethe consulting fees was offset by declines in non-clinical services as we control costs to better align with our net revenues.
     Our corporate division medical benefits expense increases as medical claims increase. The claims increase during the thirdfirst quarter of fiscal 2010. The decrease in salaries and wages was offset by a $1.7 million increase in bonus expense. Bonuses are accrued based on2011 compared to the expected attainment of operating performance and/or individual goals. During the third quarter of fiscal 2009 it was management’s estimate that the attainment of goals required for bonus payout was unlikely and a reduction in bonus expense was recorded at that time. A similar reduction was taken during the secondfirst quarter of fiscal 2010 versusis the third quarter of fiscal 2010 based on management’s current estimate ofdirect cause for the attainment of these goals for fiscal 2010.$0.4 million increase.

2522


     Repairs and maintenance costs have increased as our facilities age and also as a result of the addition of our newest hospital HMMC, which began operations in the second month of the first quarter of fiscal 2010. HMMC contributed $0.2 million of the total increase during the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010 as maintenance costs were incurred on the new facility.
     Temporary labor has increased at our corporate division to support our hospitals during the strategic options process as full-time employed positions within the corporate division have declined. As discussed below, although our temporary labor has increased for the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010, our salaries and wages for full-time employees declined by approximately $2.0 million year over year.
     Our insurance premiums increased during the first quarter of fiscal 2011 compared to the first quarter of fiscal 2011. This increase is the result of changing the structure of some of our insurance programs to account for our overall strategic environment.
     Our bonus expense is recognized as bonuses are earned. The bonus expense for the first quarter of fiscal 2011 increased $0.2 million as we anticipate more of our hospitals will meet the fiscal 2011 bonus targets based on the first quarter of fiscal 2011 results compared to the estimate for the first quarter of fiscal 2010. We evaluate the progress of our bonus programs on a quarterly basis and adjust quarterly as deemed necessary.
     Our relocation, recruiting and travel expense declined $0.4 million during the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010 due to our strategic options process. We hired several key executives during the first quarter of fiscal 2010, which contributed to a higher expense in the prior year compared to the first quarter of fiscal 2011. In addition, we have aincurred less travel expense as assets are sold.
     Our physician practice expenses have declined $0.3 million during the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010 as our primary care practice at one of our hospitals whichhas decreased the total number of physicians within the practice. Conversely, there was first organized during fiscal 2009. Thea $0.4 million decline in revenues related to the primary care practice.
     Salaries and wage expense declined $0.6 million increase in expense is a result offor the addition of physicians to the practice during the thirdfirst quarter of fiscal 20102011 compared to the first quarter of fiscal 2011 due to our strategic options process. We recognized approximately $1.0 million in severance expense and 2009.
$0.4 million in retention bonus expense during the first quarter of fiscal 2011. The $0.3 million increase in property taxesseverance and retention expense was offset by a $2.0 million decline in salaries and wages expense as corporate positions have been eliminated and/or consolidated as we align our costs with our revenues and as we sell assets that we support.
Depreciation expense.Depreciation expense decreased $1.0 million to $4.9 million for the first quarter of fiscal 2011 from $5.9 million for the first quarter of fiscal 2010. The decrease in depreciation expense is directlyprimarily attributable to the recent expansions at several of our hospitals, which has increased the tax value of our property at these locations.
     Purchased services have increased $0.4 million as a result of an increasedecrease in fixed asset depreciable base due to impairments on long-lived assets recorded in the use of outside clinicalsecond and non-clinical providers for services such as anesthesiologist, hospitalist and emergency department personnel. The increases are the result of entering into new contracts with these vendors to ensure 24 hour coverage at our hospitals.
     Repair and maintenance expense for our Hospital Division increased $0.3 million for the third quarter of fiscal 2010 when compared to the same period of fiscal 2009 to the fact that our hospitals are aging and in need of higher maintenance.
     Professional fees for the third quarter of fiscal 2010 include charges of approximately $1.7 million related to legal, audit, consulting and board of director expenses in connection with the review of our Strategic Alternatives Review. Conversely, we incurred $1.1 million in professional fees during the third quarter of fiscal 2009 associated with an internal assessment of certain controls and procedures, resulting in a $0.6 million year over year increase in professional fees related to special projects. Offsetting this increase is a decline in professional fees related to recurring professional fees as a direct result of the reduction in new corporate initiatives and an overall reduction in outstanding legal matters (see fees and licenses reduction discussion below).
     During the third quarter of fiscal 2009 we incurred $0.8 million related to the anticipated settlement of regulatory claims at two of our hospitals related to the identification, return, and self-reporting of $0.7 million in reimbursement for certain procedures performed at those hospitals in prior fiscal years. We did not incur any fees or penalties during the third quarterfourth quarters of fiscal 2010.
     Interest expense.Interest expense increased $0.7$0.2 million to $1.1 million for the thirdfirst quarter of fiscal 20102011 from $0.4$0.9 million for the thirdfirst quarter of fiscal 2009.2010. The $0.7 million increase in interest expense is primarily attributable to a slight increase in the fact that no interest expense was capitalized duringrate charged on outstanding debt and an increase in the thirdamount of assets under capital leases.
Gain on sale of equity interests.The gain on sale of equity interests of $15.4 million for the first quarter of fiscal 2010, whereas $0.8 million of interest expense was capitalized during the comparable period of fiscal 2009 due to our expansion projects and construction of HMMC. The increase in interest expense due2011 is related to the cessationsale of capitalizedour interest wasin Avera Heart Hospital of South Dakota (“AHHSD”) partially offset by a nominal loss on the overall reductionsale of the Company’s interest in our outstanding debt resulting in lower interest payments during the third quarter of fiscal 2010.Southwest Arizona Heart and Vascular Center, LLC. Such sales occurred on October 1, 2010 and November 1, 2010, respectively.
     Equity in net earnings of unconsolidated affiliates.The net earnings of unconsolidated affiliates are comprised of our share of earnings in two unconsolidated hospitals, a hospital realty investment and several ventures within our MedCath Partners Division. The Company owned two unconsolidated hospitals until the disposition of its interest in AHHSD on October 1, 2010.
     NetEquity in net earnings of unconsolidated affiliates in which we have a noncontrolling interest remained flat fromdecreased during the thirdfirst quarter of fiscal 20092011 to $0.6 million from $1.5 million for the same period of fiscal 2010. AHHSD contributed $1.0 million of net earnings during the first quarter of fiscal 2010 and was disposed on October 1, 2010 resulting in the noted decrease in such equity in net earnings. The Company expects continued decreases due to the third quarterdisposition of fiscalits interest in Southwest Arizona Heart and Vascular Center, LLC on November 1, 2010.
     Net income attributable to noncontrolling interest.Noncontrolling interest share of earnings of consolidated subsidiaries increased to $2.4$11.4 million for the thirdfirst quarter of fiscal 20102011 from $2.3$0.8 million for the third quartercomparable period of fiscal 2009. Net income attributable to noncontrolling interests on a same facility basis was as follows:
                         
  Three Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Net income attributable to noncontrolling interest $2,886  $2,273  $613   27.0%  2.3%  1.8%
2010.
     On a same facility basis, netNet income attributable to noncontrolling interest increased $0.6$7.1 million and $2.2 million due to a reductionthe noncontrolling shareholders’ interest in net incomethe gains recognized in fiscal 2011 upon the disposition of the majority of the assets of HHA and TexSan Heart Hospital, respectively. In addition, the Company recognized an increase of $0.5 million due to the losses recognized at AzHH in our disproportionate sharethe first quarter of losses from certainfiscal 2010 and the Company’s sale of our facilities.its interest in AzHH on October 1, 2010.
     We expect earnings attributable to noncontrolling interests to fluctuate in future periods as we either recognize disproportionate losses and/or recoveries thereof through disproportionate profit recognition. For a more complete discussion of our accounting for noncontrolling interests, including the basis for disproportionate allocation accounting, seeCritical Accounting Policiesin our Annual Report on Form 10-K for the fiscal year ended September 30, 2009.2010.

23


     Income tax expense (benefit) expense..Income tax benefitexpense (benefit) was $8.6an expense of $4.5 million for the thirdfirst quarter of fiscal 2011 compared to a benefit of $(1.3) million for the first quarter of fiscal 2010, compared to income tax expense of $0.2 million for the comparable period of fiscal 2009, which represents an effective tax rate of approximately 37.9%32.4% and 87.7%(66.1)% for the respective periods. The higherfirst quarter fiscal 2011 effective rate is below our federal statutory rate of 35.0% primarily due to the effect of income taxallocable to our noncontrolling interests. The first quarter fiscal 2010 effective rate foris above our federal statutory rate of 35.0% due to the three monthsrecognition of fiscal 2009 wasa disproportionate share of the resultlosses at certain of nondeductible permanent differences relatedour hospitals, partially offset by the allocation of income allocable to Medicare settlements as discussedour noncontrolling interests. The Company has recognized a disproportionate share of losses at certain of our hospitals due to cumulative losses in Note 7excess of this report.initial capitalization and committed capital of the Company’s partners or members.
     Income(Loss) income from discontinued operations, net of taxes.Income from discontinued operations primarily includes HHA for the third quarter of fiscal 2010 and 2009. Income generated by HHA has increased as a result of not recording depreciation since the asset was classified as held for sale during the second quarter of fiscal 2010.

26


Results of Operations
Nine Months Ended June 30, 2010 Compared to Nine Months Ended June 30, 2009
Statement of Operations Data.The following table presents our results of operations in dollars and as a percentage of net revenue for the periods indicated:
                         
  Nine Months Ended June 30, 
  (in thousands except percentages) 
          Increase/(Decrease)  % of Net Revenue 
  2010  2009  $  %  2010  2009 
Net revenue $390,815  $381,410  $9,405   2.5%  100.0%  100.0%
Operating expenses:                        
Personnel expense  136,055   131,884   4,171   3.2%  34.8%  34.6%
Medical supplies expense  107,453   105,829   1,624   1.5%  27.5%  27.7%
Bad debt expense  36,241   28,798   7,443   25.8%  9.3%  7.6%
Other operating expenses  89,292   81,039   8,253   10.2%  22.9%  21.2%
Pre-opening expenses  866   1,340   (474)  (35.4)%  0.2%  0.4%
Depreciation  23,054   19,179   3,875   20.2%  5.9%  5.0%
Amortization  24   24             
Impairment of property and equipment  42,761      42,761   100.0%  10.9%   
Loss on disposal of property, equipment and other assets  39   127   (88)  (69.3)%      
                   
(Loss) income from operations  (44,970)  13,190   (58,160)  (440.9)%  (11.5)%  3.5%
Other income (expenses):                        
Interest expense  (3,337)  (3,074)  (263)  8.6%  (0.9)%  (0.8)%
Loss on early extinguishment of debt     (6,702)  6,702   100.0%     (1.8)%
Interest and other income  156   220   (64)  (29.1)%     0.1%
Loss on note receivable  (1,507)     (1,507)  100.0%  (0.4)%   
Equity in net earnings of unconsolidated affiliates  6,870   7,044   (174)  (2.5)%  1.8%  1.8%
                     
(Loss) income from continuing operations before income taxes  (42,788)  10,678   (53,466)  (500.7)%  (11.0)%  2.8%
Income tax (benefit) expense  (17,929)  1,287   (19,216)  N/M   (4.6)%  0.3%
                   
(Loss) income from continuing operations  (24,859)  9,391   (34,250)  (364.7)%  (6.4)%  2.5%
Income from discontinued operations, net of taxes  3,895   8,793   (4,898)  (55.7)%  1.0%  2.3%
                   
Net (loss) income  (20,964)  18,184   (39,148)  (215.3)%  (5.4)%  4.8%
Less: Net income attributable to noncontrolling interest  (5,718)  (9,860)  4,142   (42.0)%  (1.4)%  (2.6)%
                   
Net (loss) income attributable to MedCath Corporation $(26,682) $8,324  $(35,006)  (420.5)%  (6.8)%  2.2%
                   
 
Amounts attributable to MedCath Corporation common stockholders:                        
(Loss) income from continuing operations, net of taxes $(29,246) $1,708  $(30,954)  N/M   (7.5)%  0.4%
Income from discontinued operations, net of taxes  2,564   6,616   (4,052)  (61.2)%  0.7%  1.8%
                   
Net (loss) income $(26,682) $8,324  $(35,006)  (420.5)%  (6.8)%  2.2%
                   
N/MNot meaningful
     For comparison purposes, the selected operating data below are presented on an actual basis and on a same facility basis. Same facility basis excludes HMMC from operations for the nine months ended June 30, 2010. The following table presents selected operating data on a consolidated basis and a same facility basis for the periods indicated:

27


                     
  Nine Months Ended June 30, 
              2010 Same  
  2010 2009 % Change Facility % Change
                     
Selected Operating Data (a):
                    
Number of hospitals  7   6       6     
Licensed beds ( b )  600   530       530     
Staffed and available beds ( c )  514   484       444     
Admissions ( d )  19,347   17,883   8.2%  18,176   1.6%
Adjusted admissions ( e )  28,436   25,621   11.0%  26,252   2.5%
Patient days ( f )  72,536   69,841   3.9%  68,073   (2.5)%
Adjusted patient days ( g )  107,012   100,167   6.8%  98,809   (1.4)%
Average length of stay (days) ( h )  3.75   3.91   (4.1)%  3.75   (4.1)%
Occupancy ( i )  51.7%  52.9%      56.2%    
Inpatients with a catheterization procedure (j)  8,824   8,993   (1.9)%  8,624   (4.1)%
Inpatient surgical procedures (k)  5,463   5,394   1.3%  5,237   (2.9)%
Hospital net revenue (in thousands except percentages) $377,402  $363,790   3.7% $358,086   (1.6)%
(a)Selected operating data includes consolidated hospitals in operation as of the end of the period reported in continuing operations but does not include hospitals which are accounted for using the equity method or as discontinued operations in our consolidated financial statements.
(b)Licensed beds represent the number of beds for which the appropriate state agency licenses a facility regardless of whether the beds are actually available for patient use.
(c)Staffed and available beds represent the number of beds that are readily available for patient use at the end of the period.
(d)Admissions represent the number of patients admitted for inpatient treatment.
(e)Adjusted admissions are a general measure of combined inpatient and outpatient volume. We compute adjusted admissions by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by admissions.
(f)Patient days represent the total number of days of care provided to inpatients.
(g)Adjusted patient days are a general measure of combined inpatient and outpatient volume. We compute adjusted patient days by dividing gross patient revenue by gross inpatient revenue and then multiplying the quotient by patient days.
(h)Average length of stay (days) represents the average number of days inpatients stay in our hospitals.
(i)We compute occupancy by dividing patient days by the number of days in the period and then dividing the quotient by the number of staffed and available beds.
(j)Inpatient catheterization procedures represent the number of inpatients with a procedure performed in one of the hospitals’ catheterization labs during the period.
(k)Inpatient surgical procedures represent the number of surgical procedures performed on inpatients during the period.

28


Net Revenue.Our consolidated net revenue increased 2.5% or $9.4 million to $390.8 million for the nine months ended June 30, 2010 from $381.4 million for the nine months ended June 30, 2009. Hospital Division net revenue increased 3.7% or $13.4 million, for the first nine months of fiscal 2010 compared to the same period of fiscal 2009. Beginning in our first quarter of fiscal 2010, our MedCath Partners Division renegotiated certain management contracts and several joint ventures. Consequently, certain management agreements within our MedCath Partners Division were terminated. As a result, our MedCath Partners Division net revenue declined $4.0 million during the nine months of fiscal 2010 compared to the same period of fiscal 2009. Net revenue on a same facility basis was as follows:
                         
  Nine Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Net revenue $371,499  $381,410  $(9,911)  (2.6)%  100.0%  100.0%
     Same facility inpatient net revenue was 73.6% of the Hospital Division’s same facility net patient revenue for the nine months of fiscal 2010 compared to approximately 73.0% for the same period of fiscal 2009. Our total same facility inpatient cases increased 1.6% and inpatient net revenue was down 3.6% for the nine months of fiscal 2010 compared to the comparable period of fiscal 2009. This decline in net revenue was due primarily to a 1.8% reduction in our core cardiovascular related cases, resulting in a $14.7 million reduction in total same facility core cardiovascular net patient revenue offset by a 26.5% increase in our inpatient non-core procedure related net revenue. Total outpatient net revenue, excluding emergency department net revenue, increased 6.1% due to a 22.2% increase in outpatient AICD implants, pacer implants and EP studies/ablations net revenue. These procedures have increased due to the addition of physicians performing these procedures at certain of our hospitals. Emergency department net revenue increased 8.4% due to the mix of the procedures performed and the recent expansions at certain of our hospitals.
     Net revenue for the nine months of fiscal 2010 included charity care deductions of $6.1 million compared to charity care deductions of $2.7 million for the comparable period of fiscal 2009. The $3.4 million increase is the result of more uninsured patients applying and qualifying for charity care.
Personnel expense.Our consolidated personnel expense increased 3.2% to $136.1 million for the nine months ended June 30, 2010 from $131.9 million for the comparable period of fiscal 2009. Personnel expense on a same facility basis was as follows:
                         
  Nine Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Personnel expense $125,590  $131,884  $(6,294)  (4.8)%  (33.8)%  34.6%
     The $6.3 million reduction in same facility personnel expense was primarily due to a $7.2 million reduction in salaries and wages, including temporary labor and bonuses, offset by a $0.9 million increase in employee benefits expense. We continue to experience reduction in salaries and wages as we focus on aligning our expenses with the level of care required for our patients. The total percentage of personnel expense is approximately the same for the nine months of fiscal 2010 and fiscal 2009. Our benefits expense increased as the result of an increase in the number of medical claims for the nine months of fiscal 2010 compared to the comparable period of fiscal 2009.
Medical supplies expense.Our consolidated medical supplies expense increased 1.5% to $107.5 million for the nine months of fiscal 2010 from $105.8 million for the comparable period of fiscal 2009. Medical supplies expense on a same facility basis was as follows:
                         
  Nine Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Medical supplies expense $103,866  $105,829  $(1,963)  (1.9)%  (28.0)%  27.7%
     The $2.0 million decrease to medical supplies expense for the nine months of fiscal 2010 was due to lower volumes on procedures that have high net revenue per case, such as open heart procedures. We had an 11.6% reduction in open heart surgeries for the nine months of fiscal 2010 compared to the comparable period of fiscal 2009. With less open heart net revenue, the percentage of medical supplies increases as a percentage of net revenue. In addition, we have negotiated a decline in the unit cost of our drug-eluting stents and our utilization of stents per case has declined.

29


Bad debt expense.Our consolidated bad debt expense increased 25.8% to $36.2 million for the nine months of fiscal 2010 from $28.8 million for the comparable period of fiscal 2009. As a percentage of net revenue, bad debt expense increased to 9.3% for the nine months of fiscal 2010 as compared to 7.6% for the comparable period of fiscal 2009. Bad debt expense on a same facility basis was as follows:
                         
  Nine Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Bad debt expense $33,288  $28,798  $4,490   15.6%  9.0%  7.6%
     Our total same facility Hospital Division uncompensated care including charity care and bad debt expense was 10.9% of total same facility net patient hospital revenue for the nine months of fiscal 2010 compared to 8.6% of total same facility net patient revenue for the comparable period of fiscal 2009. The total number of patients which applied and qualified for charity care increased during first quarter of fiscal 2010 compared to the first quarter of fiscal 2009. We reported $3.4 million more charity deductions to net revenue during the nine months of fiscal 2010 when compared to the comparable period of fiscal 2009. Bad debt expense alone (not including charity care) increased $4.5 million for the nine months of fiscal 2010 compared to the comparable period of fiscal 2009. This is attributable to an increase in the self-pay portion of accounts balance after insurance plans and a corresponding increase in the percent of these accounts we believe are uncollectible for the nine months of fiscal 2010 compared to the same period of fiscal 2009.
Other operating expenses.Our consolidated other operating expenses increased 10.2% to $89.3 million for the nine months of fiscal 2010 from $81.0 million for the comparable period of fiscal 2009. Other operating expense on a same facility basis was as follows:
                         
  Nine Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Other operating expense $82,112  $81,039  $1,073   1.3%  22.1%  21.2%
     Our same facility other operating expense increased $1.1 million for the nine months of fiscal 2010 compared to the comparable period of fiscal 2009. The material and notable increases in operating expenses were as reflected below (in millions):
     
Employee benefits $1.4 
Purchased contract services $1.2 
Professional fees $0.8 
Repairs and maintenance $0.7 
Travel $(0.5)
Fees and penalties $(0.8)
Corporate salaries, wages, bonus, recruitment and temporary labor $(0.9)
Advertising expense $(1.2)
Professional liability expense $(1.6)
     Our corporate benefits expense was approximately $1.4 million higher due to an increase in employee medical claims during the nine months of fiscal 2010 compared to the same period of fiscal 2009.
     Purchased contract services have increased $1.2 million as a result of an increase in the use of outside clinical and non-clinical providers for services such as anesthesiologist, hospitalist and emergency department personnel. The increases are the result of entering into new contracts with these vendors to ensure 24 hour coverage at our hospitals.
     Our professional fees were $0.8 million higher for the nine months of fiscal 2010 compared to the comparable period of fiscal 2009 due to fees incurred related to the pending sale of HHA and fees related to our Strategic Alternatives Review.
     We incurred an additional $0.7 million of repairs and maintenance expense during the nine months of fiscal 2010 compared to the comparable period of fiscal 2009 as our newer facilities begin to age.
     Travel expense has declined during the nine months of fiscal 2010 compared to the comparable period of fiscal 2009 due to the reduction in the number of managed ventures in our MedCath Partners Division, which required travel to these facilities during fiscal 2009, and a reduction in corporate travel as we have ceased any travel related to new initiatives.

30


     During the nine months of fiscal 2009 we incurred $0.8 million related to penalty expense for the anticipated settlement of regulatory claims at two of our hospitals related to the identification, return and self-reporting of $0.7 million in reimbursement for certain procedures performed at those hospitals in prior fiscal years. We did not incur any fees or penalties during the nine months of fiscal 2010.
     Our corporate salary related expenses including bonuses, recruitment and temporary labor has declined $0.9 million for the nine months of fiscal 2010 compared to the comparable period for fiscal 2009. The decline is primarily due to the attrition we have experienced as a result of Strategic Alternatives Review as well as a reduction in temporary labor and recruiting expense as new initiatives have declined.
     Advertising expense was $1.2 million lower during the nine months of fiscal 2010 compared to the same period of fiscal 2009. We ran several advertising campaigns during the nine months of fiscal 2009 to promote our expanded facilities and to increase volumes in our emergency departments.
     Our medical malpractice expense was $1.6 million lower for the nine months of fiscal 2010 compared to the same period of fiscal 2009 due to specific high dollar claims incurred in fiscal 2009.
Interest expense.Interest expense increased $0.2 million or 8.6% to $3.3 million for the nine months of fiscal 2010 from $3.1 million for the comparable period of fiscal 2009. The $0.2 million increase in interest expense is primarily attributable to the fact that no interest was capitalized during the nine months of fiscal 2010, whereas $2.3 million of interest was capitalized during the comparable period of fiscal 2009. This increase was offset by our overall reduction in our outstanding debt and interest rates on our outstanding debt.
Loss on note receivable.Our corporate and other division entered into a note receivable agreement with a third party during 2008. The note receivable was deemed uncollectable and a loss of $1.5 million was recorded during the three month period ended March 31, 2010, due to our determination of the third party’s inability to repay the note and the insufficiency of the value of the collateral securing the note.
Equity in net earnings of unconsolidated affiliates.The net earnings of unconsolidated affiliates are comprised of our share of earnings in two unconsolidated hospitals, a hospital realty investment and several ventures within our MedCath Partners Division.
     Net earnings of unconsolidated affiliates in which we have a noncontrolling interest decreased during the nine months of fiscal 2010 to $6.9 million from $7.0 million for the same period of the prior year. The $0.1 million decrease was primarily due to hospitals in our Hospital Division in which we hold a noncontrolling interest.
Net(Loss) income attributable to noncontrolling interest.Noncontrolling interest share of earnings of consolidated subsidiaries decreased to $5.7 million for the nine months of fiscal 2010 from $9.9 million for the comparable period of fiscal 2009. Net income attributable to noncontrolling interest on a same facility basis was as follows:
                         
  Nine Months Ended June 30,
  (in thousands except percentages)
          Increase/(Decrease) % of Net Revenue
  2010 2009 $ % 2010 2009
Net income attributable to noncontrolling interest $8,004  $9,860  $(1,856)  (18.8)%  2.2%  2.6%
     On a same facility basis, net income attributable to noncontrolling interest decreased $1.9 million due to a reduction in net income and an increase in our disproportionate share of losses from certain of our facilities.
     We expect earnings attributable to noncontrolling interests to fluctuate in future periods as we either recognize disproportionate losses and/or recoveries thereof through disproportionate profit recognition. For a more complete discussion of our accounting for noncontrolling interests, including the basis for disproportionate allocation accounting, seeCritical Accounting Policiesin our Annual Report on Form 10-K for the fiscal year ended September 30, 2009.
Income tax (benefit) expense.Income tax benefit was $17.9 million for the nine months of fiscal 2010 compared to income tax expense of $1.3 million for the comparable period of fiscal 2009, which represents an effective tax rate of approximately 38.0% and 43.0% for the respective periods. The higher income tax rate for the nine months of fiscal 2009 was the result of nondeductible permanent differences related to Medicare settlements as discussed in Note 7 of this report.
Income from discontinued operations, net of taxes.Discontinued operations decreasedtaxes increased to income of $2.6$26.1 million, net of taxes for the nine monthsfirst quarter of fiscal 20102011 from incomea loss of $6.6$1.1 million, net of taxes, for the comparable period of fiscal 2009. Income from discontinued operations during the nine months of fiscal 2010 reflected the operations of HHA and the related continued activities associated with DHH, which primarily related to accounts receivable and medical malpractice reserves. Income from discontinued operations from the same period of fiscal 2009 reflected the operating income from HHA, Sun City, Cape Cod, and the gain from the divestiture of Cape Cod, which was sold during2010. During the first quarter of fiscal 2009,2011, the Company recognized pre-tax gains upon disposition of assets of discontinued operations of $69.9 million, partially offset by lossesan $11.1 million loss on early termination of debt at DHH.one of the facilities. The significant components of the gains recognized are a $35.7 million gain and a $34.3 million gain on the sale of the assets of HHA and TexSan Heart Hospital, respectively. In addition, pretax loss from operating activities of the discontinued businesses decreased $1.0 million.

31


Liquidity and Capital Resources
     Working Capital and Cash Flow Activities. Our consolidated working capital from continuing operations was $50.5 million at June 30, 2010 and $35.1 million at September 30, 2009. Consolidated working capital from continuing operations increased $15.4 million due to an $8.4 million reduction in accounts payable due to a decrease in overall operating expenses, a $2.6 million decrease in other accrued liabilities primarily due to the final payments of our development costs associated with HMMC and LMCHH, and a decrease in the current portion of long-term debt of $6.1 million due to the payment of notes payable related to our consolidated subsidiary, TexSAn Heart Hospital.
     At June 30, 2010, we continue to carry a reserve of $9.8 million for outlier payments received in 2004, which is recorded in current liabilities of discontinued operations.
     Cash provided by continuing operations from operating activities was $24.8 million for the nine months of fiscal 2010 compared to $45.7 million for the comparable period of fiscal 2009. The decrease of $20.9 million in cash provided by continuing operations from operating activities was due to an overall increase in bad debt reserves and final payments of $2.3$0.5 million and $0.6 million related to our development costs associated with HMMC and LMCHH, respectively, duringfor the ninefirst three months of fiscal 20102011 compared to $2.0 million for the comparable period of fiscal 2009.2010.
     Our investing activities from continuing operations usedprovided net cash of $16.3$32.1 million for the ninefirst three months of fiscal 20102011 compared to $67.2a use of cash of $7.5 million for the comparable period of fiscal 2009. The total cash used2010. Such increase is primarily due to the net proceeds of $31.9 million for capital expenditures decreased by $50.9 millionthe disposition of the Company’s interest in Avera Heart Hospital of South Dakota and Southwest Arizona Heart and Vascular LLC during the nine monthsfirst quarter of fiscal 20102011. In addition, the Company experienced a decrease of $7.4 million in cash paid for property and equipment in the first quarter of fiscal 2011 as compared to the comparablesame period in fiscal 2010. This decrease is primarily related to the capital expenditures in fiscal 2010 related to the development of fiscal 2009, a direct result of the completion of the expansion of our hospital facilities and the opening of HMMC.Hualapai Mountain Medical Center, which opened in October 2009.
     Our financing activities from continuing operations used net cash of $27.4$12.9 million for the ninefirst three months of fiscal 20102011 compared to $43.1$12.3 million for the comparable period of fiscal 2009.2010. Cash used in financing activities decreased $15.7to repay long-term debt and obligations under capital leases increased $2.8 million for the ninefirst three months of fiscal 20102011 as compared to the comparable period of fiscal 2009. The decrease2010. This increase was due to the repayment of our 9 7/8% Senior Notes during December 2008partially offset by a $10.6decrease of $2.4 million payment on our Credit Facility duringin distributions to noncontrolling shareholders. Subsequent to the nine monthsend of the first quarter of fiscal 2010.2011, the Company made an additional $20.6 million prepayment of its outstanding balance under the Amended Credit Facility.
     Capital Expenditures.Cash paid for property and equipment was $16.8$0.2 million and $68.0$7.5 million for the ninefirst three months of fiscal years 20102011 and 2009,2010, respectively. Of the $16.8$7.5 million of cash paid for property and equipment during the ninefirst three months of fiscal 2010, $8.8$3.7 million related to maintenance capital expenditures. The $68.0 million cash paid for property and equipment during the nine months of fiscal 2009 primarily related to the development of HMMC and the expansion projects at two of our existing hospitals. All expansion projects were substantially complete during fiscal 2009, and HMMCHualapai Mountain Medical Center, which opened in October 2009.
     Obligations and Availability of Financing.At June 30,December 31, 2010, we had $79.5$67.4 million of outstanding long-term debt and obligations under capital leases, of which $15.8$61.6 million was classified as current. Our Term Loan under our Amended Credit Facility had an outstanding amount of $69.4 million as of June 30, 2010.$58.9 million. The remaining outstanding long-term debt and obligationsobligation under capital leases of $10.1$8.5 million was due to various lenders to our Hospital Division and MedCath Partners Division.hospitals. No amounts were outstanding under our Revolver. The maximum availability under our Revolver is $85.0$59.5 million which wasis reduced by outstanding letters of credit totaling $1.7 million as of June 30,December 31, 2010. As previously noted, on January 5, 2011 the Company made a principal prepayment of $20.6 million of the amounts outstanding under the Amended Credit Facility.
     Covenants related to our long-term debt restrict the payment of dividends and require the maintenance of specific financial ratios and amounts and periodic financial reporting. AtHowever, as noted inLiquidity and Capital Resourcesin our Annual Report on Form 10-K for the fiscal year ended September 30, 2009, TexSAn Heart Hospital2010, the Company was in violation of financial covenants which govern its equipment loans outstanding. Accordingly,not required to test the total outstanding balance for these loans of $6.1 million has been included infixed charge coverage ratio at December 31, 2010 and will retest such compliance at the current portion of long-term debtfiscal quarter ended March 31, 2011 and obligations under capital leases in our consolidated balance sheet. These loans were fully repaid as of June 30, 2010. The covenant violations did not result in any other non-compliance related to the covenants governing our other outstanding debt arrangements. As of June 30, 2010 we were in compliance with all of our covenants.subsequent fiscal quarters.
     At June 30,December 31, 2010, we guaranteed either all or a portion of the obligations of certain of our subsidiary hospitals for equipment and other notes payable.equipment. We provide these guarantees in accordance with the related hospital operating agreements, and we receive a fee for providing these guarantees from either the hospitals or the physician investors. Access to available borrowings under our Amended Credit Facility is dependent on the Company’s ability to maintain compliance with the financial covenants contained in the Amended Credit Facility. Deterioration in the Company’s operating results could result in failure to maintain compliance with these covenants, which would restrict or eliminate access to available funds.
     We believe that internally generated cash flows from operations and available borrowings under our Credit Facilityasset sales will be sufficient to finance our business plan,strategic plans, capital expenditures and our working capital requirements for the next 12 to 18 months. Repayment of the outstanding balance under our Amended Credit Facility prior to its November 2011 maturity date will be dependent on existing cash, cash flow from operations and cash from asset sales. On January 5, 2011, the Company prepaid $20.6 million of the outstanding balance using the proceeds from asset dispositions, thereby reducing the outstanding balance under the Amended Credit Facility to $38.3 million at that date.

24


Intercompany Financing Arrangements.We provide secured real estate, equipment and working capital financings to our majority-owned hospitals. Each intercompany real estate loan is separately documented and secured with a lien on the borrowing hospital’s real estate, building and equipment and certain other assets. Each intercompany real estate loan typically matures in 7 to 10 years and accrues interest at variable rates based on LIBOR plus an applicable margin or a fixed rate similar to terms commercially available.
     Each intercompany equipment loan is separately documented and secured with a lien on the borrowing hospital’s equipment and certain other assets. Amounts borrowed under the intercompany equipment loans are payable in monthly installments of principal and interest over terms that range from 5 to 7 years. The intercompany equipment loans accrue interest at rates ranging from 4.87% to 8.43%. The weighted average interest rate for the intercompany equipment loans at December 31, 2010 was 7.09%.
     We typically receive a fee from the minority partners in the subsidiary hospitals as further consideration for providing these intercompany real estate and equipment loans.
     We also use intercompany financing arrangements to provide cash support to individual hospitals for their working capital and other corporate needs. We provide these working capital loans pursuant to the terms of the operating agreements between our physician and hospital investor partners and us at each of our hospitals. These intercompany loans are evidenced by promissory notes that establish borrowing limits and provide for a market rate of interest to be paid to us on outstanding balances. These intercompany loans are subordinate to each hospital’s mortgage and equipment debt outstanding, but are senior to our equity interests and our partners’ equity interests in the hospital venture and are secured, subject to the prior rights of the senior lenders, in each instance by a pledge of certain of the borrowing hospital’s assets. Also as part of our intercompany financing and cash management structure, we sweep cash from individual hospitals as amounts are available in excess of the individual hospital’s working capital needs. These funds are advanced pursuant to cash management agreements with the individual hospital that establish the terms of the advances and provide for a rate of interest to be paid consistent with the market rate earned by us on the investment of its funds. These cash advances are due back to the individual hospital on demand and are subordinate to our equity investment in the hospital venture.
     The estimated net realizable value of intercompany notes outstanding with the Company’s subsidiaries in continuing operations was $153.2 million and $149.8 million as of September 30, 2010 and December 31, 2010, respectively. All intercompany notes are eliminated in consolidation and are not reflected on the Company’s consolidated balance sheet.
Retained Obligations Subsequent to Disposition.Included in discontinued operations are certain liabilities that the Company has retained upon the disposition of the related entity. As the Company’s hospitals are organized as partnerships, upon disposition of the related operations, assets and certain liabilities, the partnerships are responsible for the resolution of outstanding payables, remaining obligations, including those related to cost reports, medical malpractice and other obligations and wind down of the respective tax filings of the partnership. The partnerships are also responsible for any unknown liabilities that may arise. The Company has reported all known obligations in its consolidated balance sheets as of December 31, 2010 and September 30, 2010. However, as the ultimate resolution of the outstanding payables and obligations may take in excess of one year, our estimates may prove incorrect and result in the Company paying amounts in excess of those recorded at the respective balance sheet date.
Retained Cash Balance.At December 31, 2010 the Company had $158.5 million in cash related to continuing operations and $45.4 million in cash related to discontinued operations. The Company expects to retain approximately $156.4 million of the $158.5 million cash in continuing operations after it distributes cash from certain hospital partnerships to itself and the minority owners of those partnerships. As of December 31, 2010 the Company’s estimate of total potential cash distributions to the Company from discontinued operations after it distributes cash from the respective hospital partnerships is approximately $25.7 million after taking into account distributions to minority owners, the liquidation of all assets and the settlement of all known liabilities, but does not take into account any unknown contingent liabilities related to the discontinued operations. The estimate of total cash distributions to the Company may change as it updates its estimates. There can be no assurance when the distributions to the Company from discontinued operations may take place, but it may be over an extended period of time. Any cash retained will be used to fund working capital and repay outstanding debt, which is due in full in November 2011.
Disclosure About Critical Accounting Policies
     Our accounting policies are disclosed in our Annual Report on Form 10-K for the year ended September 30, 2009.2010. During the ninefirst three months of fiscal 20102011 we adopted a new accounting policiespolicy as discussed in Note 2 —Recent Accounting Pronouncementsto our consolidated financial statements included herein.statements. The adoption of thesethis new accounting policiespolicy did not have a material impact on our consolidated financial statements.

32


Forward-Looking Statements
     Some of the statements and matters discussed in this report and in exhibits to this report constitute forward-looking statements, including statements relating to the impact of statutory and regulatory changes, including reimbursement rates, our payor mix, earnings attributable to noncontrolling interests in hospitals, the consummation of asset dispositions, and our boards consideration of strategic alternatives to maximize stockholders’ value.statements. Words such as “expects,” “anticipates,” “approximates,” “believes,” “estimates,” “intends” and “hopes” and variations of such words and similar expressions are intended to identify such forward-looking statements. We have based these statements on our current expectations and projections about future events. These forward- lookingforward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these statements. Although we believe that these statements are based upon reasonable assumptions, we cannot assure you that we will achieve our goals. In light

25


of these risks, uncertainties and assumptions, the forward-looking events discussed in this report and its exhibits might not occur. Our forward-looking statements speak only as of the date of this report or the date they were otherwise made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We urge you to review carefully all of the information in this report and our other filings with the SEC, including the discussion of risk factors inItem 1A. Risk Factorsin this report and our Annual Report on Form 10-K for the year ended September 30, 2009 as may be updated by2010, before making an investment decision with respect to our subsequent filings with the SEC.equity securities. A copy of this report, including exhibits, is available on the internet site of the SEC athttp://www.sec.govor through our website athttp://www.medcath.com.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
     We maintain a policy for managing risk related to exposure to variability in interest rates, commodity prices, and other relevant market rates and prices which includes considering entering into derivative instruments (freestanding derivatives), or contracts or instruments containing features or terms that behave in a manner similar to derivative instruments (embedded derivatives) in order to mitigate our risks. In addition, we may be required to hedge some or all of our market risk exposure, especially to interest rates, by creditors who provide debt funding to us. The Company disposed of its minority interest in a hospital that maintained a cash flow hedge on October 1, 2010. As a result, the Company does not have outstanding any derivatives at December 31, 2010. There was no material change in our policy for managing risk related to variability in interest rates, commodity prices, other relevant market rates and prices during the first ninethree months of 2010.2011. See Item 7A in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 20092010 for further discussions about market risk.
Interest Rate Risk
     Our Amended Credit Facility borrowings expose us to risks caused by fluctuations in the underlying interest rates. The total outstanding balance of our Credit Facility was $69.4$58.9 million at June 30,December 31, 2010. A change of 100 basis points in the underlying interest rate would have caused a change in interest expense of approximately $0.5$0.1 million during the ninethree month period ended June 30, 2010.December 31, 2011.
Item 4. Controls and Procedures
     The President and Chief Executive Officer and the Executive Vice President and Chief Financial Officer of the Company (its principal executive officer and principal financial officer, respectively) have concluded, based on their evaluation of the Company’s disclosure controls and procedures as of June 30,December 31, 2010, that the Company’s disclosure controls and procedures were effective as of June 30,December 31, 2010 to ensure that information required to be disclosed by the Company in the reports filed or submitted by it under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported in a timely manner, and includes controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files under the Exchange Act is accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. There were no changes during the fiscal quarter to the Company’s internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

33


PART II. OTHER INFORMATION
Item 1. Legal Proceedings
     We are occasionally involved in legal proceedings and other claims arising out of our operations in the normal course of business. See Note 7 —Contingencies and Commitmentsto the consolidated financial statements included in this report.
Item 1A. Risk Factors
     Information concerning certain risks and uncertainties appears under the heading “Forward-Looking Statements” in Part I, Item 2 of this report and Part I, Item 1A of our Annual Report on Form 10-K for the year ended September 30, 2009.2010. You should carefully consider these risks and uncertainties.uncertainties before making an investment decision with respect to our securities. Such risks and uncertainties could materially adversely affect our business, financial condition or operating results.
     During the period covered by this report, there have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended September 30, 20092010 or filings subsequently made with the Securities and Exchange Commission, except for the addition of the following risk factors:
Impairment of long-lived assets could have a material adverse effect on our consolidated financial statements
     Long-lived assets, which include finite lived intangible assets, are evaluated for impairment when events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset and its eventual disposition are less than its carrying amount. The determination of whether or not long-lived assets have become impaired involves a significant level of judgment in the assumptions underlying the approach used to determine the estimated future cash flows expected to result from the use of those assets. Changes in our strategy, assumptions and/or market conditions could significantly impact these judgments and require adjustments to recorded amounts of long-lived assets. If impairment is determined to be present, the resulting non-cash impairment charges could be material to our consolidated financial statements.
Health Reform Laws may have a material adverse impact on our financial condition and results of operations
     On March 23, 2010, President Obama signed into law the Patient Protection and Affordable Care Act, followed by the Health Care and Education Reconciliation Act of 2010 on March 30, 2010 (collectively referred to as the “Health Reform Laws”). The Health Reform Laws include many provisions that will affect our Company, although given the complexity of the laws, the full impact on the Company and its operations is not known at this time. In addition, implementing regulations have not been issued which will also have a bearing on how these changes impact the Company. Some of the provisions in the Health Reform Laws are effective immediately while others will not become effective for several years.
     Significantly, the Health Reform Laws revised the “whole hospital” exception to the Stark Law by adding additional requirements for hospitals to qualify for the exception. Because all of our hospitals have physician ownership and therefore must comply with the “whole hospital” exception, these additional requirements will apply to all of our hospitals. These requirements include: additional reporting and disclosure obligations; prohibitions on the increase in the percentage of physician ownership over that in place on the date of enactment; prohibitions on expanding the number of beds, operating rooms, or procedure rooms over the number in place as of the date of enactment, specifications for physician investment; and patient safety measures. The limitations on expansion and additional investment by physician owners or investors were effective as to our hospitals as of March 23, 2010.
     The Health Reforms Laws also established a new Independent Payment Advisory Board (the “IPAB”) to develop and submit proposals to Congress to reduce Medicare spending. The IPAB could have a significant impact on Medicare spending, which in turn would affect Medicare payments to our hospitals and other health care facilities.
     Some of the other provisions contained in the Health Reform Laws may have a positive impact on the Company, such as the expansion in the number of individuals with health insurance and the expansion of Medicaid eligibility. The Health Reform Laws also tie payment to quality measures by establishing a value-based purchasing system and adjusting hospital payment rates based on hospital-acquired conditions and hospital readmissions. Beginning in 2013, hospitals that satisfy certain performance standards will receive increased payments for discharges during the following fiscal year. We believe that if we continue to make quality of care improvements, this may have the effect of reducing costs, increasing payments from Medicare for our services, and increasing physician and patient satisfaction.

34


     The Health Reform Laws also include enhanced government enforcement tools to identify and impose remedies for fraud, which may adversely impact entities in the healthcare industry, including our Company.
     In addition, certain provisions of the Health Reform Laws authorize voluntary demonstration projects beginning not later than 2013 for bundling payments for acute, inpatient hospital services, physician services, and post acute services for episodes of hospital care. In addition, beginning no later than January 1, 2012, the Health Reform Laws allows providers organized as accountable care organizations that voluntarily meet quality thresholds to share in the cost savings they achieve for the Medicare program.
The Company is unable to predict at this time the full impact of the Health Reform Laws on the Company and its operations.
Commission.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
     On July 27, 2001, we completed an initial public offering of our common stock pursuant to our Registration Statement on Form S-1 (File No. 333-60278) that was declared effective by the SEC on July 23, 2001. We expect to use the remaining proceeds of approximately $13.8 million from the offering to fund development activities, working capital requirements and other corporate purposes. Although we have identified these intended uses of the remaining proceeds, we have broad discretion in the allocation of the net proceeds from the offering. Pending this application, we will continue to invest the net proceeds of the offering in cash and cash-equivalents, such as money market funds or short-term interest bearing, investment-grade securities.
     The Board of Directors approved a stock repurchase program of up to $59.0 million in August 2007, which was announced November 2007. Stock purchases can be made from time to time in the open market or in privately negotiated transactions in accordance with applicable federal and state securities laws and regulations. The repurchase program may be discontinued at any time. Subsequent to the approval of the stock repurchase program, the Company has purchased 1,885,461 shares of common stock at a total cost of $44.4 million, with a remaining $14.6 million available to be repurchased per the approved stock repurchase program. No shares were repurchased during the nine month period ended June 30, 2010.
     See Note 6 to our annual financial statements in our Annual Report on Form 10-K for the year ended September 30, 2009 for a description of restrictions on payments of dividends and stock repurchases.

35


Item 6. Exhibits
   
Exhibit No. Description
2.1Membership Interest Purchase Agreement effective as of November 1, 2010 by and among Southwest Arizona Heart and Vascular Center, LLC and MedCath Partners, LLC(1)
2.2Amendment to the Asset Purchase Agreement dated as of October 29, 2010 by and between St. David’s Healthcare Partnership, L.P., LLC and Heart Hospital IV, L.P. (1)

26


Exhibit No.Description
2.3Asset Purchase Agreement dated as of November 5, 2010 by and between Methodist Healthcare System of San Antonio, LTD., L.L.P. and Heart Hospital of San Antonio, LP(2)
3.1Amended and Restated Bylaws of MedCath Corporation(3)
10.1*Amendment to Employment Agreement dated and effective December 30, 2010 by and between MedCath Corporation and O. Edwin French
10.2*Amendment to Employment, Confidentiality and Non-Compete Agreement dated April 29, 2010 by and between MedCath Corporation and James A. Parker
10.3*Amendment to Employment, Confidentiality and Non-Compete Agreement dated and effective December 30, 2010 by and between MedCath Corporation and James A. Parker
10.4*Employment, Confidentiality and Non-Compete Agreement effective October 29, 2009 by and between MedCath Incorporated and Daniel Perritt
10.5*Form of Indemnification Agreement entered into by MedCath with each of its directors and officers(4)
10.6Call Agreement dated as of October 4, 2010 by and among Hualapai Mountain Medical Center Management, Inc. and the undersigned Investor Members of Hualapai Mountain Medical Center, LLC.(3)
10.7*Release and Separation Agreement dated as of November 11, 2010 by and between David Bussone and MedCath Corporation(5)
   
31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*Indicates a management contract or compensatory plan or agreement.
(1)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 4, 2010.
(2)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 9, 2010.
(3)Incorporated by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2010.
(4)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 26, 2010.
(5)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 15, 2010.

27


SIGNATURES
     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
     
 MEDCATH CORPORATION
 
 
Dated: AugustFebruary 9, 20102011 By:  /s/ O. EDWIN FRENCH   
  O. Edwin French  
  President and Chief Executive Officer
(principal executive officer) 
 
 
   
 By:  /s/ JAMES A. PARKER   
  James A. Parker  
  Executive Vice President and
Chief Financial Officer (principal financial officer) 
 
 
   
 By:  /s/ LORA RAMSEY   
  Lora Ramsey  
  Vice President and Controller
(principal accounting officer) 
 

3628


     
INDEX TO EXHIBITS
   
Exhibit No. Description
2.1Membership Interest Purchase Agreement effective as of November 1, 2010 by and among Southwest Arizona Heart and Vascular Center, LLC and MedCath Partners, LLC(1)
2.2Amendment to the Asset Purchase Agreement dated as of October 29, 2010 by and between St. David’s Healthcare Partnership, L.P., LLC and Heart Hospital IV, L.P. (1)
2.3Asset Purchase Agreement dated as of November 5, 2010 by and between Methodist Healthcare System of San Antonio, LTD., L.L.P. and Heart Hospital of San Antonio, LP(2)
3.1Amended and Restated Bylaws of MedCath Corporation(3)
10.1*Amendment to Employment Agreement dated and effective December 30, 2010 by and between MedCath Corporation and O. Edwin French
10.2*Amendment to Employment, Confidentiality and Non-Compete Agreement dated April 29, 2010 by and between MedCath Corporation and James A. Parker
10.3*Amendment to Employment, Confidentiality and Non-Compete Agreement dated and effective December 30, 2010 by and between MedCath Corporation and James A. Parker
10.4*Employment, Confidentiality and Non-Compete Agreement effective October 29, 2009 by and between MedCath Incorporated and Daniel Perritt
10.5*Form of Indemnification Agreement entered into by MedCath with each of its directors and officers(4)
10.6Call Agreement dated as of October 4, 2010 by and among Hualapai Mountain Medical Center Management, Inc. and the undersigned Investor Members of Hualapai Mountain Medical Center, LLC.(3)
10.7*Release and Separation Agreement dated as of November 11, 2010 by and between David Bussone and MedCath Corporation(5)
   
31.1 Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
31.2 Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
   
32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
   
32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
*Indicates a management contract or compensatory plan or agreement.
(1)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 4, 2010.
(2)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 9, 2010.
(3)Incorporated by reference from the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2010.
(4)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 26, 2010.
(5)Incorporated by reference from the Company’s Current Report on Form 8-K filed November 15, 2010.

3729